☐
|
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 |
☒ |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐
|
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Japan
|
1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku, Tokyo 103-8668, Japan
|
||||
(Jurisdiction of incorporation or organization) | (Address of principal executive offices) |
Title of Each Class | Trading Symbols |
Name of Each Exchange On Which Registered
|
||||||
American Depositary Shares Representing Common Stock
Common Stock, no par value* |
TAK | New York Stock Exchange | ||||||
0.750% Senior Notes due 2027 | TAK27 | New York Stock Exchange | ||||||
1.000% Senior Notes due 2029 | TAK29 | New York Stock Exchange | ||||||
1.375% Senior Notes due 2032 | TAK32 | New York Stock Exchange | ||||||
2.000% Senior Notes due 2040 | TAK40A | New York Stock Exchange |
Large accelerated filer | ý | Accelerated filer | ☐ | Non-accelerated filer | ☐ | Emerging growth company | ☐ |
U.S. GAAP ☐
|
International Financial Reporting Standards as issued
by the International Accounting Standards Board ý |
Other ☐ |
PART III
|
|||||
For the fiscal year ended March 31, | |||||||||||||||||||||||||||||
2017 | 2018 | 2019 | 2020 | 2021 | |||||||||||||||||||||||||
(billions of yen, except share and per share data and where designated as U.S. dollar) | |||||||||||||||||||||||||||||
Selected Statements of Operations Data: | |||||||||||||||||||||||||||||
Revenue | ¥ | 1,732.1 | ¥ | 1,770.5 | ¥ | 2,097.2 | ¥ | 3,291.2 | ¥ | 3,197.8 | |||||||||||||||||||
Operating profit | 155.9 | 241.8 | 237.7 | 100.4 | 509.3 | ||||||||||||||||||||||||
Share of profit (loss) of investments accounted for using the equity method | (1.5) | (32.2) | (43.6) | (24.0) | 0.1 | ||||||||||||||||||||||||
Profit (loss) before tax | 143.3 | 217.2 | 127.6 | (60.8) | 366.2 | ||||||||||||||||||||||||
Net profit for the year | 115.5 | 186.7 | 135.1 | 44.3 | 376.2 | ||||||||||||||||||||||||
Net profit attributable to owners of the Company
|
114.9 | 186.9 | 135.2 | 44.2 | 376.0 | ||||||||||||||||||||||||
Per share amounts | |||||||||||||||||||||||||||||
Basic earnings | ¥ | 147.15 | ¥ | 239.35 | ¥ | 140.61 | ¥ | 28.41 | ¥ | 240.72 | |||||||||||||||||||
Diluted earnings | 146.26 | 237.56 | 139.82 | 28.25 | 238.96 | ||||||||||||||||||||||||
Annual cash dividends | 180.00 | 180.00 | 180.00 | 180.00 | 180.00 | ||||||||||||||||||||||||
Cash dividends in U.S. dollars(1)
|
$ | 1.62 | $ | 1.69 | $ | 1.63 | $ | 1.67 | $ | 1.63 | |||||||||||||||||||
Selected Statements of Financial Position Data:
|
|||||||||||||||||||||||||||||
Cash and cash equivalents | ¥ | 319.5 | ¥ | 294.5 | ¥ | 702.1 | ¥ | 637.6 | ¥ | 966.2 | |||||||||||||||||||
Total assets | 4,346.8 | 4,106.5 | 13,792.8 | 12,821.1 | 12,912.3 | ||||||||||||||||||||||||
Total bonds and loans | 1,144.9 | 985.7 | 5,751.0 | 5,093.3 | 4,635.4 | ||||||||||||||||||||||||
Total liabilities | 2,397.8 | 2,089.1 | 8,606.8 | 8,093.6 | 7,735.1 | ||||||||||||||||||||||||
Total equity | 1,949.0 | 2,017.4 | 5,186.0 | 4,727.5 | 5,177.2 | ||||||||||||||||||||||||
Share capital | 65.2 | 77.9 | 1,643.6 | 1,668.1 | 1,668.1 | ||||||||||||||||||||||||
Other Data: | |||||||||||||||||||||||||||||
Number of shares issued at end of period (in thousands)
|
790,521 | 794,688 | 1,565,006 | 1,576,374 | 1,576,388 |
TAK-609
|
Recombinant human iduronate-2-sulfatase for intrathecal administration (injection)
|
Biologic and other | Hunter syndrome CNS |
U.S.
EU
|
P-II
P-II
|
||||||||||||
TAK-611
|
Recombinant human arylsulfatase A for intrathecal administration (injection)
|
Biologic and other | Metachromatic leukodystrophy |
-
|
P-II | ||||||||||||
TAK-079(3)
<mezagitamab>
|
Anti-CD38 monoclonal antibody (injection)
|
Biologic and other | Myasthenia gravis |
-
|
P-II
|
||||||||||||
Immune thrombocytopenic purpura |
-
|
P-II
|
|||||||||||||||
Systemic lupus erythematosus |
-
|
P-I/II
|
|||||||||||||||
TAK-834
NATPARA (U.S.),
NATPAR (EU)
|
Parathyroid hormone (injection)
|
Biologic and other | Hypoparathyroidism |
Japan
|
P-I(4)
|
TAK-861
|
Orexin 2R agonist (oral)
|
Small molecule | Narcolepsy |
-
|
P-I | ||||||||||||
TAK-925
|
Orexin 2R agonist (injection)
|
Small molecule |
Narcolepsy, other sleep disorders
|
-
|
P-I |
Development code
Brand name
(country/region)
|
Type of vaccine
(administration route)
|
Modality
|
Indications / additional formulations
|
Stage
|
|||||||||||||
TAK-003
|
Tetravalent dengue vaccine (injection)
|
Biologic and other | For the prevention of dengue fever of any severity, due to any serotype, in individuals aged 4 up to 60 years of age |
EU and EU-M4all
-
|
Filed (Mar 2021)(4)
P-III
|
||||||||||||
TAK-919/mRNA-1273(1)
|
COVID-19 vaccine (injection)
|
Biologic and other |
Active immunization for the prevention of COVID-19
|
Japan |
Filed (Mar 2021)(5)
|
||||||||||||
TAK-019/NVX‑CoV2373(2)
|
COVID-19 vaccine (injection)
|
Biologic and other |
Active immunization for the prevention of COVID-19
|
Japan |
P-I/II
|
||||||||||||
TAK-214
|
Norovirus vaccine (injection)
|
Biologic and other | Active immunization for the prevention of acute gastroenteritis caused by norovirus | - |
P-II (b)
|
||||||||||||
TAK-426(3)
|
Zika vaccine (injection)
|
Biologic and other | Active immunization for the prevention of disease caused by Zika virus | - |
P-I
|
Our product |
Japan expiry dates(1)(2)
|
U.S. expiry dates(1)
|
EU expiry dates(1)
|
||||||||
Gastroenterology (GI):
|
|||||||||||
ENTYVIO |
Patent: -
RP: July 2026(2) |
Patent: September 2021
RDP: May 2026(8)
|
Patent: August 2017 (Extended expiry of August 2022 in certain countries)
RDP: May 2024(8)
|
||||||||
DEXILANT | Not commercialized | Patent: - | Patent: - | ||||||||
PANTOLOC /CONTROLO
(PANTOPRAZOLE)
|
Not commercialized | Patent: - | Patent: - | ||||||||
TAKECAB(3)
|
Patent: August 2031
RP: December 2022(2)
|
Patent: -(3)
|
Patent: -(3)
|
||||||||
GATTEX/REVESTIVE | Not commercialized |
Patent: -(5)
|
Patent: -
RDP: September 2024 |
||||||||
PENTASA(4)
|
Patent: -(4)
|
Patent: - |
Patent: -(4)
|
||||||||
LIALDA/MEZAVANT(3)
|
Patent: - (3)
RP: September 2022(2) |
Patent: - | Patent: - | ||||||||
AMITIZA(4)
|
Patent: -(4)
|
Patent: May 2021(6)
|
Not commercialized | ||||||||
RESOLOR/MOTEGRITY | Not commercialized |
Patent: -
RDP: December 2023 |
Patent: -
|
Our product |
Japan expiry dates(1)(2)
|
U.S. expiry dates(1)
|
EU expiry dates(1)
|
||||||||
Rare Metabolic: | |||||||||||
ELAPRASE (3)
|
Patent: - (3)
|
Patent: - | Patent: - | ||||||||
REPLAGAL | Patent: - | Not commercialized | Patent: - | ||||||||
VPRIV |
Patent: -
RP: July 2024(2) |
Patent: - |
Patent: -
RDP: August 2022 |
||||||||
NATPARA/NATPAR
|
Not commercialized |
Patent: -
RDP: January 2027 |
Patent: -
RDP: April 2029 |
||||||||
Rare Hematology: | |||||||||||
ADVATE | Patent: - | Patent: - | Patent: - | ||||||||
ADYNOVATE/ADYNOVI |
Patent: January 2026
RP: March 2024(2) |
Patent: February 2026
RDP: November 2027 |
Patent: January 2028 if granted
RDP: January 2028 |
||||||||
FEIBA(7)
|
Patent: - | Patent: - | Patent: - | ||||||||
HEMOFIL(7)
|
Not commercialized | Patent: - | Not commercialized | ||||||||
IMMUNATE(7)
|
Not commercialized | Not commercialized | Patent: - | ||||||||
IMMUNINE(7)
|
Not commercialized | Not commercialized | Patent: - | ||||||||
BEBULIN(7)
|
Not commercialized | Patent: - | Not commercialized | ||||||||
PROTHROMPLEX(7)
|
Not commercialized | Not commercialized | Patent: - | ||||||||
FACTOR VII(7)
|
Not commercialized | Not commercialized | Patent: - | ||||||||
VONVENDI |
Patent: -
RP: March 2030(2)
|
Patent: December 2030
RDP: December 2027 |
Patent: -
RDP: August 2028 |
||||||||
OBIZUR | Not commercialized |
Patent: -
RDP: October 2026 |
Patent: February 2026
RDP: November 2025 |
||||||||
RIXUBIS |
Patent: -
RP: December 2022(2) |
Patent: -
|
Patent: - | ||||||||
AGRYLIN/XAGRID |
Patent: -
RP: September 2024(2) |
Patent: - | Patent: - | ||||||||
RECOMBINATE | Not commercialized | Patent: - | Not commercialized | ||||||||
Hereditary Angioedema: | |||||||||||
FIRAZYR |
Patent: -
RP: September 2028(2) |
Patent: - |
Patent: -
|
||||||||
TAKHZYRO |
Patent: January 2031
Extended expiry of September 2035 if PTE granted |
Patent: December 2031, February 2032, March 2032
Extended expiry of August 2032 if PTE granted
RDP: August 2030
|
Patent: January 2031 (Extended expiry of November 2033 in some countries)
RDP: November 2028
|
||||||||
KALBITOR | Not commercialized | Patent: December 2023 | Not commercialized | ||||||||
CINRYZE(7)
|
Not commercialized |
Patent: -
|
Patent: - | ||||||||
Plasma-Derived Therapies (PDT) Immunology:
|
|||||||||||
GAMMAGARD LIQUID(7)
|
Not commercialized | Patent: - | Patent: - | ||||||||
HYQVIA(7)
|
Not commercialized |
Patent: -
RDP: September 2026 |
Patent: -
RDP: May 2024 |
||||||||
CUVITRU(7)
|
Not commercialized |
Patent: -
RDP: September 2028 |
Patent: -
RDP: July 2027 |
||||||||
FLEXBUMIN(7)
|
Not commercialized | Patent: - | Patent: - | ||||||||
HUMANALBUMIN(7)
|
Not commercialized | Not commercialized | Patent: - | ||||||||
GLASSIA(7)
|
Patent: -(4)
|
Patent: -
RDP: July 2022 |
Patent: -(4)
|
Our product |
Japan expiry dates(1)(2)
|
U.S. expiry dates(1)
|
EU expiry dates(1)
|
||||||||
ARALAST(7)
|
Not commercialized | Patent: - | Not commercialized | ||||||||
CEPROTIN(7)
|
Not commercialized | Patent: - | Patent: - | ||||||||
ANTITHROMBIN III(7)
|
Not commercialized | Not commercialized | Patent: - | ||||||||
KENKETU-GLOVENIN-I(7)
|
Patent: - | Not commercialized | Not commercialized | ||||||||
KENKETU-NONTHRON(7)
|
Patent: - | Not commercialized | Not commercialized | ||||||||
KENKETU-ALUBMIN(7)
|
Patent: - | Not commercialized | Not commercialized | ||||||||
Oncology: | |||||||||||
VELCADE(3)
|
Patent: -(3)
|
Patent: - |
Patent: -(3)
|
||||||||
LEUPLIN/ENANTONE | Patent: - | Patent: - | Patent: - | ||||||||
NINLARO |
Patent: July 2031
RP: March 2027(2) |
Patent: November 2029
RDP: November 2022 |
Patent: November 2031
RDP: November 2026 |
||||||||
ADCETRIS(4)
|
Patent: April 2026
RP: January 2024(2) |
Patent: -(4)
|
Patent: October 2027
RDP: October 2023, January 2028
|
||||||||
ICLUSIG(3)
|
Patent: -(3)
|
Patent: January 2027 |
Patent: -(3)
|
||||||||
ALUNBRIG |
Patent:November 2032
RP: January 2029
|
Patent: July 2030
Extended expiry of April 2031 if PTE granted RDP: April 2024 |
Patent: May 2029
Extended expiry of November 2033 if SPC granted RDP: November 2028 |
||||||||
VECTIBIX(4)
|
Patent: August 2022 |
Patent: -(4)
|
Patent: -(4)
|
||||||||
CABOMETYX(4)
|
Patent: September 2024
Extended expiry of September 2029 of PTE granted |
Patent: -(4)
|
Patent: -(4)
|
||||||||
Neuroscience:
|
|||||||||||
VYVANSE/ELVANSE |
Patent: June 2029
RP: March 2027(2) |
Patent: February 2023 | Patent: June 2024 (Extended expiry of February 2028 or March 2029 in certain countries) | ||||||||
TRINTELLIX (4)
|
Patent: October 2027
RP: September 2027(2) |
Patent: December 2026
Extended expiry of December 2026 if pediatric exclusivity (PED) granted |
Patent: -(4)
|
||||||||
ADDERALL XR | Not commercialized | Patent: - | Not commercialized | ||||||||
ROZEREM | Patent: March 2022 | Patent: - | Not commercialized | ||||||||
REMINYL | Patent: - |
Patent: -(4)
|
Patent: - | ||||||||
INTUNIV |
Patent: -
RP: March 2025(2) |
Patent: - |
Patent: -
RDP: September 2025 |
||||||||
COPAXONE(4)
|
Patent: -
RP: September 2025(2) |
Patent: -(4)
|
Patent: -(4)
|
||||||||
AZILECT(4)
|
Patent: -
RP: March 2026(2) |
Patent: -(4)
|
Patent: -(4)
|
||||||||
MYDAYIS | Not commercialized |
Patent: -
|
Not commercialized | ||||||||
EQUASYM | Not commercialized |
Patent: -(3)
|
Patent: - | ||||||||
CARBATROL | Not commercialized |
Patent: -
|
Not commercialized |
Our product |
Japan expiry dates(1)(2)
|
U.S. expiry dates(1)
|
EU expiry dates(1)
|
||||||||
Other: | |||||||||||
AZILVA-F |
Patent: -
RP: October 2021(2) |
Not commercialized | Not commercialized | ||||||||
NESINA/VIPIDIA-F |
Patent: -(3)
|
Patent: June 2028 | Patent: September 2028 | ||||||||
ULORIC(4)
|
Patent: -(4)
|
Patent: - |
Patent: -(4)
|
||||||||
COLCRYS | Not commercialized | Patent: - | Not commercialized | ||||||||
LOTRIGA(4)
|
Patent: -
|
Patent: - (4)
|
Patent: - (4)
|
Partner | Country | Description of collaboration | ||||||
Oncology: | ||||||||
Adimab | U.S. | Agreement for the discovery, development and commercialization of three mAbs and three CD3 Bi-Specific antibodies for oncology indications. | ||||||
Centre d'Immunologie de Marseille-Luminy | France | Collaboration agreement to bring together expertise and knowledge in innate biology with Takeda’s BacTrap capabilities to identify novel targets and pathways in myeloid cells. | ||||||
ASKA Pharmaceutical Co., Ltd | Japan | Takeda granted exclusive commercialization rights for uterine fibroids and exclusive development and commercialization rights for endometriosis for Japan to maximize the product value of relugolix (TAK-385). | ||||||
Crescendo Biologics | U.K | Collaboration and licensing agreement for the discovery, development and commercialization of Humabody®-based therapeutics for cancer indications. | ||||||
Egle Therapeutics | France | Identify novel tumor-specific regulatory T-cell targets and develop unique anti-suppressor-based immunotherapies. | ||||||
Exelixis, Inc. | U.S. | Exclusive licensing agreement to commercialize and develop novel cancer therapy cabozantinib and all potential future cabozantinib indications in Japan, including advanced renal cell carcinoma and hepatocellular carcinoma. | ||||||
GammaDelta Therapeutics | U.K. | Collaboration agreement to discover and develop new immunotherapies in oncology using GammaDelta Therapeutics' novel T cell platform based on the unique properties of gamma delta T cells derived from human tissues. | ||||||
GlaxoSmithKline | U.K. | Exclusive licensing agreement to develop and commercialize novel cancer therapy niraparib for the treatment of all tumor types in Japan, and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia. | ||||||
Heidelberg Pharma | Germany | Antibody-Drug-Conjugate (ADC) research collaboration on 2 targets and licensing agreement (α-amanitin payload and proprietary linker). | ||||||
KSQ Therapeutics | U.S. | Strategic collaboration to research, develop and commercialize novel immune-based therapies for cancer using KSQ’s CRISPRomics® technology | ||||||
MD Anderson Cancer Center | U.S. | Exclusive license and research agreement to develop cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies, ‘armored’ with IL-15, for the treatment of B-cell malignancies and other cancers | ||||||
Memorial Sloan Kettering Cancer Center | U.S. | Strategic research collaboration and license to develop novel chimeric antigen receptor T-cell (CAR-T) products for the treatment of multiple myeloma, acute myeloid leukemia and additional solid tumor indications. The collaboration is co-led by Michel Sadelain, who is currently head of the Center for Cell Engineering at Memorial Sloan Kettering | ||||||
Molecular Templates | U.S. | Molecular Templates will continue to develop TAK-169 and Takeda will maintain its equity stake in Molecular Templates. | ||||||
Myovant Sciences | Switzerland | Takeda granted Myovant an exclusive, worldwide license (excluding Japan and certain other Asian countries) to relugolix (TAK-385) and an exclusive, worldwide license to MVT-602 (TAK-448). | ||||||
National Cancer Center of Japan | Japan | Partnership agreement to develop basic research to clinical development by promoting exchanges among researchers, physicians, and others engaged in anti-cancer drug discovery and cancer biology research. | ||||||
Noile-Immune Biotech | Japan | Collaboration agreement for the development of next generation CAR-T cell therapy, developed by Professor Koji Tamada at Yamaguchi University. Takeda has exclusive options to obtain licensing rights for the development and commercialization of Noile-Immune Biotech's pipeline and products resulting from this partnership. Due to the success of the collaboration, Takeda licensed NIB-102 and NIB-103. | ||||||
Presage Biosciences | U.S. | Research collaboration and license for multiple programs using Presage’s proprietary platform CIVO to evaluate patients' unique responses to microdoses of cancer drugs. | ||||||
Shattuck Labs | U.S. | Collaboration agreement to explore and develop checkpoint fusion proteins utilizing Shattuck’s unique Agonist Redirected Checkpoint (ARC)™ platform which enables combination immunotherapy with a single product. Takeda will have the option to take an exclusive license to further develop and commercialize TAK-252/SL-279252 | ||||||
Teva | Israel | Agreement for worldwide License to TEV-48573 (TAK-573) (CD38-Attenukine) and multi-target discovery collaboration accessing Teva’s attenukine platform. | ||||||
Turnstone Biologics | U.S. | Collaboration to co-develop TAK-605 (RIVAL-01) (novel oncolytic virus expressing aCTLA4, IL12-mb, flt3L) via a worldwide partnership and also conduct collaborative discovery efforts to identify additional novel product candidates based on a Turnstone’s vaccinia virus platform. |
Partner | Country | Description of collaboration | ||||||
Rare genetics and hematology: | ||||||||
Asklepios Biopharmaceuticals | U.S. | Agreement for multiple research and development collaborations using FVIII Gene Therapy for the treatment of Hemophilia A and B. | ||||||
BioMarin | U.S. | Agreement for the in-license of enabling technology for the exogenous replacement of iduronate-2-sulfatase with Idursulfase-IT in patients via direct delivery to the CNS for the long-term treatment of Hunter Syndrome in patients with cognitive impairment in order to slow progression of cognitive impairment (TAK-609). | ||||||
Carmine Therapeutics | Singapore | Research collaboration agreement to discover, develop and commercialize transformative non-viral gene therapies for two rare disease targets using Carmine's REGENT(TM) technology, based on red blood cell extracellular vesicles. | ||||||
Codexis, Inc. | U.S. | Strategic collaboration and license for the research and development of novel gene therapies for certain disease indications, including the treatment of lysosomal storage disorders and blood factor deficiencies. | ||||||
Ensoma | U.S. | Research collaboration and license provides Takeda with an exclusive worldwide license to Ensoma’s Engenious™ vectors for up to five rare disease indication, | ||||||
Evox Therapeutics | U.K. | Collaboration for developing novel protein replacement and mRNA therapies and targeted delivery using Evox’s proprietary exosome technology. Partnership for up to five rare disease targets with Takeda assuming responsibility for its clinical development | ||||||
GlaxoSmithKline | U.K. | In-license agreement between GSK and University of Michigan for TAK-620 (maribavir) in the treatment of human cytomegalovirus. | ||||||
IPSEN | France | Purchase agreement for the development of Obizur for the treatment of Acquired Hemophilia A including for patients with Congenital Hemophilia A with inhibitors indication in elective or emergency surgery. | ||||||
KM Biologics | Japan | Agreement for the development collaboration of TAK-755 to overcome the ADAMTS13 deficiency in TTP. | ||||||
Rani Therapeutics | U.S. | Research collaboration agreement to evaluate a micro tablet pill technology for oral delivery of FVIII therapy in hemophilia | ||||||
Xenetic Biosciences | U.S. | Exclusive R&D license agreement for PolyXen delivery technology for hemophilia factors VII, VIII, IX, X. | ||||||
Neuroscience: | ||||||||
Anima Biotech | U.S. | Strategic collaboration to discover and develop mRNA translation modulators for genetically-defined neurological diseases | ||||||
AstraZeneca | UK | Agreement for the joint development and commercialization of MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease. | ||||||
Bridgene | U.S. | Research collaboration to discover small molecule drugs for “undruggable” targets using Bridgene’s chemoproteomics platform | ||||||
Denali Therapeutics | U.S. | Strategic option and collaboration agreement to develop and commercialize up to three specified therapeutic product candidates for neurodegenerative diseases, incorporating Denali’s ATV platform for increased exposure of biotherapeutic products in the brain. | ||||||
Neurocrine Biosciences | U.S. | Collaboration to develop and commercialize compounds in Takeda’s early-to-mid stage neuroscience pipeline, including TAK-041, TAK-653 and TAK-831. Takeda will be entitled to certain development milestones, commercial milestones and royalties on net sales. At certain development events, Takeda may elect to opt in or out of a 50:50 profit share on all clinical programs on an asset-by-asset basis. For any asset in which Takeda is participating in a 50:50 profit share arrangement, Takeda will not be eligible to receive development or commercial milestones. | ||||||
PeptiDream | Japan | Collaborative research and exclusive license agreement to create peptide-drug conjugates (PDCs) for neuromuscular diseases | ||||||
Skyhawk Therapeutics | U.S. | Collaboration and licensing agreement to develop and commercialize RNA modulation therapies targeting neurodegenerative diseases. | ||||||
StrideBio | U.S. | Collaboration and license agreement to develop in vivo AAV based therapies for Friedreich’s Ataxia (FA) and two additional undisclosed targets. | ||||||
Wave Life Sciences | Singapore | Research, development and commercial collaboration and multi-program option agreement to develop antisense oligonucleotides for a range of neurological diseases. |
Partner | Country | Description of collaboration | ||||||
Gastroenterology (GI):
|
||||||||
Ambys Medicines | U.S. | Collaboration agreement for the application of novel modalities, including cell and gene therapy and gain-of-function drug therapy, to meet the urgent need for treatments that restore liver function and prevent the progression to liver failure across multiple liver diseases. Under the terms of the agreement, Takeda has an option to ex-U.S. commercialization rights for the first 4 products that reach an investigational new drug application. | ||||||
Arcturus | U.S. | Collaboration agreement to develop RNA-based therapeutics for the treatment of non-alcoholic steatohepatitis and other gastrointestinal related disorders using Arcturus’ wholly-owned LUNAR™ lipid-mediated delivery systems and UNA Oligomer chemistry. | ||||||
Arrowhead Pharmaceuticals | U.S. | Collaboration and licensing agreement to develop TAK-999 (ARO-AAT), a Phase 2 investigational RNA interference (RNAi) therapy in development to treat alpha-1 antitrypsin-associated liver disease (AATLD). ARO-AAT is a potential first-in-class therapy designed to reduce the production of mutant alpha-1 antitrypsin protein, the cause of AATLD progression. | ||||||
Beacon Discovery | U.S. | Collaboration agreement for the G-protein coupled receptor drug discovery and development program to identify drug candidates for a range of gastrointestinal disorders. The agreement grants Takeda worldwide rights to develop, manufacture and commercialize products resulting from the collaboration. | ||||||
Cerevance | U.S. | Multi-year research alliance to identify novel target proteins expressed in the central nervous system and to develop new therapies against them for certain GI disorders. Goal of the collaboration is to select, confirm and validate targets from gene expression data sets generated by Cerevance’s NETSseq technology. | ||||||
Cour Pharmaceutical Development Company | U.S. | Takeda has acquired an exclusive global license to develop and commercialize the investigational medicine TIMP-GLIA (TAK-101), an immune modifying nanoparticle containing gliadin proteins. | ||||||
Engitix | U.K. | Collaboration and licensing agreement to utilize Engitix’s liver fibrosis platform to conduct research activities and to nominate, confirm, and validate potential targets against which Takeda may advance new therapeutic programs. | ||||||
Enterome | France | Collaboration agreement to research and develop microbiome targets thought to play crucial roles in gastrointestinal disorders, including inflammatory bowel diseases (e.g. ulcerative colitis). The agreement includes a global license and co-development of EB8018/TAK-018 in Crohn’s disease. | ||||||
Finch Therapeutics | U.S. | Global agreement to develop FIN-524, a live biotherapeutic product composed of cultured bacterial strains linked to favorable clinical outcomes in studies of microbiota transplantations in inflammatory bowel disease. Under the terms of the agreement, Takeda obtains the exclusive worldwide rights to develop and commercialize FIN-524 and rights to follow-on products in inflammatory bowel diseases. | ||||||
Genevant Sciences Corporation | U.S. | Collaboration and License Agreement to leverage Genevant’s hepatic stellate cell-partitioning LNP platform to deliver Takeda-designed RNAi oligonucleotides intended to halt or reverse the progression of liver fibrosis. | ||||||
Hemoshear Therapeutics | U.S. | Collaboration agreement for novel target and therapeutic development for liver diseases, using Hemoshear’s proprietary REVEAL-Tx drug discovery platform. | ||||||
NuBiyota | Canada | Agreement for the development of Microbial Ecosystem Therapeutic products for gastroenterology indications. | ||||||
Phathom Pharmaceuticals | U.S. | Takeda has granted a license to Phathom Pharmaceuticals for the development and exclusive commercialization rights to vonoprazan in the U.S., Europe and Canada in exchange for upfront cash and equity, as well as future cash milestones and royalties on net sales. | ||||||
Samsung Bioepis | Korea | Strategic collaboration agreement to jointly fund and co-develop multiple novel biologic therapies in unmet disease areas. The program’s first therapeutic candidate is TAK-671, which is intended to treat severe acute pancreatitis. | ||||||
Silence Therapeutics | U.K. | Technology Evaluation Agreement with Silence Therapeutics to access their GalNAc-siRNA technology platform. The objective of the evaluation is to identify a GalNAc-conjugated siRNA that inhibits expression of a proprietary Takeda target. | ||||||
Theravance Biopharma | U.S. | Global license, development and commercialization agreement for TAK-954, a selective 5-HT4 receptor agonist for motility disorders. | ||||||
UCSD/Fortis Advisors | U.S. | Technology license for the development of oral budesonide formulation (TAK-721) for treatment of eosinophilic esophagitis. | ||||||
Plasma-Derived Therapies (PDT):
|
||||||||
Halozyme | U.S. | Agreement for the in-license of Halozyme’s proprietary ENHANZE™ platform technology to increase dispersion and absorption of HyQvia. Ongoing development work for a U.S. pediatric indication to treat primary immunodeficiencies and a Phase 3 indication in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. | ||||||
Kamada | Israel | In-license agreement to develop and commercialize IV Alpha-1 proteinase inhibitor (Glassia); Exclusive supply and distribution of Glassia in the U.S., Canada, Australia and New Zealand; work on post market commitments ongoing. | ||||||
ProThera Biologics | U.S. | Global licensing agreement to develop a novel plasma-derived Inter-alpha Inhibitor Proteins (IAIP) therapy for the treatment of acute inflammatory conditions. |
Partner | Country | Description of collaboration | ||||||
Vaccines: | ||||||||
Biological E. Limited | India | Takeda agreed to transfer existing measles and acellular pertussis vaccine bulk production technology to develop low-cost combination vaccines for India, China and low- and middle-income countries. | ||||||
U.S. Government - The Biomedical Advanced Research and Development Authority (BARDA) | U.S. | Partnership to develop TAK-426, a Zika vaccine candidate, for the U.S. with the option to use data generated for filing also in affected regions around the world. | ||||||
Novavax | U.S. | Partnership for the development, manufacturing and commercialization of over 250 million doses per year of TAK-019 (NVX‑CoV2373), Novavax’ COVID‑19 vaccine candidate, in Japan, which is being funded by the Government of Japan’s Ministry of Health, Labour and Welfare.(MHLW) and Agency for Medical Research and Development (AMED). | ||||||
Moderna | U.S. | Three-way agreement with Moderna and the Government of Japan’s Ministry of Health Labour & Welfare (MHLW) to import and distribute 50 million doses of TAK-919 (mRNA-1273) Moderna’s COVID-19 vaccine candidate, in Japan from the first half of 2021. | ||||||
Other / Multiple Therapeutic Areas: | ||||||||
Bridge Medicines | U.S. | Partnership with Tri-Institutional Therapeutics Discovery Institute, Bay City Capital and Deerfield Management in the establishment of Bridge Medicines. Bridge Medicines will give financial, operational and managerial support to move projects seamlessly from a validating, proof-of-concept study to an in-human clinical trial. | ||||||
Center for iPS Cell Research Application, Kyoto University (CiRA) | Japan | Collaboration agreement for clinical applications of iPS cells in Takeda strategic areas including applications in neurosciences, oncology and GI as well as discovery efforts in additional areas of compelling iPSC translational science. | ||||||
Charles River Laboratories | U.S. | Collaboration on multiple integrated programs across Takeda’s core therapeutic areas using Charles River Laboratories’ end-to-end drug discovery and safety assessment platform to progress these programs towards candidate status. | ||||||
Evotec GT | Germany | Research alliance to support Takeda’s growing number of research stage gene therapy discovery programs. | ||||||
HiFiBio | U.S. | Collaboration agreement for functional therapeutics high-throughput antibody discovery platform that enables identification of antibodies for rare events for discovery of therapeutic antibodies for GI and Oncology therapeutic areas. | ||||||
Massachusetts Institute of Technology | U.S. | MIT-Takeda Program to fuel the development and application of artificial intelligence (AI) capabilities to benefit human health and drug development. Centered within the Abdul Latif Jameel Clinic for Machine Learning in Health (J-Clinic), the new program will leverage the combined expertise of both organizations, and is supported by Takeda’s three-year investment (with the potential for a two-year extension). | ||||||
Portal Instruments | U.S. | Agreement for the development and commercialization of Portal’s jet injector drug delivery device for potential use with Takeda’s investigational or approved biologic medicines. | ||||||
Schrödinger | U.S. | Agreement for the multi-target research collaboration combining Schrödinger’s in silico platform-driven drug discovery capabilities with Takeda’s deep therapeutic area knowledge and expertise in structural biology. | ||||||
Seattle Collaboration | U.S. | Agreement for SPRInT (Seattle Partnership for Research on Innovative Therapies) to accelerate the translation of Fred Hutchinson Cancer Research Center's and University of Washington’s cutting-edge discoveries into treatments for human disease (focusing on Oncology, GI and Neuroscience). | ||||||
Stanford University | U.S. | Collaboration agreement with Stanford University to form the Stanford Alliance for Innovative Medicines to more effectively develop innovative treatments and therapies. | ||||||
Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) | U.S. | Agreement for the collaboration of academic institutions and industry to more effectively develop innovative treatments and therapies. | ||||||
Twist Bioscience | U.S. | Agreement and license for Takeda to access Tiwst’s “Library of Libraries,” a panel of synthetic antibody phage display libraries derived only from sequences that exist in the human body. Together, the companies will work to discover, validate and optimize new antibody candidates. |
Our product | Principal competing product | Primary manufacturer or distributor | ||||||||||||
GI: | ||||||||||||||
DEXILANT, PANTOPRAZOLE (Protonix) | generic lansoprazole, esomeprazole | — | ||||||||||||
ENTYVIO |
Remicade
Humira
Simponi
Stelara
Cimzia
generic infliximab |
Janssen Biotech
Abbvie Janssen Biotech Janssen Biotech UCB — |
||||||||||||
TAKECAB |
Nexium
generic lansoprazole, omeprazole
|
AstraZeneca
— |
||||||||||||
GATTEX/REVESTIVE
|
Zorbtive | EMD/Serono | ||||||||||||
Nutrestore | Emmaus LifeSciences | |||||||||||||
ALOFISEL |
Autologous tissue, chronic seton usage
Remicade
generic infliximab
|
—
Janssen Biotech
—
|
||||||||||||
Rare Diseases: | ||||||||||||||
ADVATE and ADYNOVATE | Xyntha/Refacto AF | Pfizer and Sobi | ||||||||||||
Kogenate | Bayer | |||||||||||||
Helixate | CSL | |||||||||||||
Kovaltry | Bayer | |||||||||||||
Iblias | CSL | |||||||||||||
Eloctate/Elocta | Sanofi and Sobi | |||||||||||||
Novoeight | Novo Nordisk | |||||||||||||
Nuwiq | Octapharma | |||||||||||||
Afstyla | CSL | |||||||||||||
Hemlibra | Roche | |||||||||||||
TAKHZYRO |
Ruconest
Generic Icatibant
Haegarda
Berinert
Orladeyo
|
Pharming
—
CSL
CSL
BioCryst
|
||||||||||||
REPLAGAL |
Fabrazyme
Galafold Fabagal |
Genzyme
Amicus Isu Abaxis |
||||||||||||
VPRIV |
Cerezyme
Elelyso/uplyso Zavesca Cerdelga Abcertin |
Sanofi Genzyme
Pfizer/Protalix
Actelion [Janssen]
Sanofi Genzyme
Isu Abxis
|
||||||||||||
Elaprase
|
Hunterase
IZCARGO
|
Korean Green Cross
JCR Pharmaceuticals
|
Our product | Principal competing product | Primary manufacturer or distributor | ||||||||||||
PDT | ||||||||||||||
GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D | Privigen | CSL | ||||||||||||
Carimune | CSL | |||||||||||||
Gamunex-C | Grifols | |||||||||||||
Flebogamma | Grifols | |||||||||||||
Bivigam
|
ADMA
|
|||||||||||||
Gammaked | Kendrion | |||||||||||||
Gammaplex | BPL | |||||||||||||
Octagam | Octapharma | |||||||||||||
Panzya | Octapharma | |||||||||||||
GAMMAGARD LIQUID, HYQVIA, CUVITRU | Hizentra | CSL | ||||||||||||
Gamunex-C | Grifols | |||||||||||||
Cutaquig/Gammanorm
|
Octapharma
|
|||||||||||||
FLEXBUMIN and
HUMAN ALBUMIN
|
Alburex/AlbuRx
|
CSL | ||||||||||||
Albuminar, Albumex
|
CSL | |||||||||||||
Plasbumin
|
Grifols | |||||||||||||
Albutein | Grifols | |||||||||||||
Albunorm | Octapharma | |||||||||||||
Kedbumin, Albuked
|
Kendrion
|
|||||||||||||
Oncology: | ||||||||||||||
ADCETRIS |
Keytruda
|
Merck/MSD
|
||||||||||||
Opdivo
|
Bristol-Myers Squibb
|
|||||||||||||
ALUNBRIG |
Xalkori
Zykadia Alecensa Lorbrena |
Pfizer
Novartis Roche Pfizer |
||||||||||||
ICLUSIG |
Gleevec
Tasigna Sprycel Bosulif |
Novartis
Novartis Bristol-Myers Squibb Pfizer |
||||||||||||
LEUPRORELIN (LEUPLIN) |
Zoladex
generic leuprorelin |
AstraZeneca
— |
||||||||||||
NINLARO, VELCADE |
Revlimid
Pomalyst/Imnovid
Kyprolis
Darzalex
Empliciti
Xpovio
Sarclisa
Papexto
Abecma
|
Bristol-Myers Squibb
Bristol-Myers Squibb
Amgen
Janssen Biotech
Bristol-Myers Squibb
Karyopharm
Sanofi
Oncopeptide
Bristol-Myers Squibb
|
||||||||||||
Neuroscience: | ||||||||||||||
TRINTELLIX |
Viibryd
Fetzima
Generics: Amitriptyline, amoxapine, bupropion, citalopram, clomipramine, desipramine, desvenlafaxine, doxepin, duloxetine, esketamine, escitalopram, fluoxetine, fluvoxamine, imipramine, maprotiline, mirtazapine, nefazodone, nomifensine, nortriptyline, nefazodone, paroxetine, protriptyline, sertraline, trazodone, trimipramine, venlafaxine
|
AbbVie
AbbVie
Various
|
Our product | Principal competing product | Primary manufacturer or distributor | ||||||||||||
VYVANSE |
generic mixed salts of a single-entity amphetamine product:
–Adderall IR
|
Various | ||||||||||||
generic mixed salts of a single-entity amphetamine product, extended release:
–Adderall XR
|
Various | |||||||||||||
generic methylphenidate, extended release:
–Concerta
–Jornay PM
–Adhansia XR
|
Various
Ironshore Pharmaceuticals
Adlon Therapeutics
|
|||||||||||||
Non-stimulants:
–Strattera (atomoxetine)
–Intuniv (guanfacine)
–Kapvay (clonidine)
|
Various | |||||||||||||
Other: | ||||||||||||||
AZILVA | generic candesartan, olmesartan | — | ||||||||||||
NESINA |
Januvia
generic pioglitazone
|
Merck Co., Inc.
— |
Group company | Location | Use of facility |
Land Area
(in square meter) |
||||||||
Takeda Pharmaceutical Company Limited | Chuo-ku,Tokyo, Japan |
Global Headquarters
(Administrative and sales) |
13,102 | ||||||||
Takeda Pharmaceutical Company Limited | Chuo-ku, Osaka, Japan |
Head Office(1)
(Administrative and sales)
|
443,441 | ||||||||
Takeda Pharmaceutical Company Limited | Hikari-shi, Yamaguchi, Japan | Production, research and development | 1,011,061 | ||||||||
Takeda Pharmaceutical Company Limited | Fujisawa-shi, Kanagawa, Japan | Research and development | 22,749 | ||||||||
Millennium Pharmaceuticals, Inc. | Cambridge, MA, U.S. | Research and development, others | 144,675 | ||||||||
Takeda Ireland Limited | Kilruddery, Ireland | Production, others | 202,679 | ||||||||
Baxalta US Inc. | Covington, GA, U.S. | Production, others | 507,617 | ||||||||
Shire Human Genetic Therapies, Inc | Lexington, MA, U.S. | Production, others | 399,192 | ||||||||
Baxter AG | Vienna, Austria | Production, others | 368,551 | ||||||||
Baxalta Manufacturing S.a.r.l. | Neuchatel, Switzerland | Production, others | 87,264 | ||||||||
Baxalta Belgium Manufacturing S.A. | Lessines, Belgium | Production, others | 135,538 | ||||||||
BioLife Plasma Services LP | Bannockburn, IL, U.S. | Production, others | 425,289 | ||||||||
Baxalta Bioscience Manufacturing S.a.r.l, Singapore Branch | Singapore | Production, others | — |
|
For the fiscal year ended March 31, | ||||||||||||||||||||||
2020 | 2021 | Change versus the previous year | |||||||||||||||||||||
(billions of yen, except percentages) | |||||||||||||||||||||||
Revenue | ¥ | 3,291.2 | ¥ | 3,197.8 | ¥ | (93.4) | (2.8) | % | |||||||||||||||
Effect of exchange rates | (77.2) | ||||||||||||||||||||||
Revenue at constant exchange rates | 3,291.2 | 3,275.0 | (16.2) | (0.5) | % |
For the Year Ended March 31,
|
|||||||||||||||||||||||
2020 | 2021 | Change versus the previous year | |||||||||||||||||||||
(billions of yen, except for percentages) | |||||||||||||||||||||||
Gastroenterology: | |||||||||||||||||||||||
ENTYVIO | ¥ | 347.2 | ¥ | 429.3 | ¥ | 82.1 | 23.6 | % | |||||||||||||||
TAKECAB-F (1)
|
72.7 | 84.8 | 12.1 | 16.7 | |||||||||||||||||||
GATTEX/REVESTIVE | 61.8 | 64.6 | 2.8 | 4.5 | |||||||||||||||||||
DEXILANT | 62.8 | 55.6 | (7.2) | (11.5) | |||||||||||||||||||
PANTOLOC/CONTROLOC (2)
|
49.5 | 43.1 | (6.3) | (12.8) | |||||||||||||||||||
ALOFISEL | 0.4 | 0.8 | 0.4 | 110.2 | |||||||||||||||||||
Others(4)
|
103.5 | 99.7 | (3.9) | (3.8) | |||||||||||||||||||
Total Gastroenterology | 697.9 | 777.8 | 79.9 | 11.4 | |||||||||||||||||||
Rare Diseases: | |||||||||||||||||||||||
Rare Metabolic: | |||||||||||||||||||||||
ELAPRASE | 67.9 | 68.8 | 0.9 | 1.3 | |||||||||||||||||||
REPLAGAL | 51.3 | 51.8 | 0.5 | 1.0 | |||||||||||||||||||
VPRIV | 38.0 | 38.5 | 0.5 | 1.3 | |||||||||||||||||||
NATPARA/NATPAR | 13.6 | 3.6 | (10.1) | (74.0) | |||||||||||||||||||
Total Rare Metabolic | 170.8 | 162.6 | (8.2) | (4.8) | |||||||||||||||||||
Rare Hematology: | |||||||||||||||||||||||
ADVATE | 157.9 | 128.5 | (29.3) | (18.6) | |||||||||||||||||||
ADYNOVATE/ADYNOVI | 58.7 | 58.1 | (0.6) | (1.0) | |||||||||||||||||||
FEIBA | 51.5 | 44.5 | (7.0) | (13.6) | |||||||||||||||||||
RECOMBINATE | 17.1 | 13.4 | (3.7) | (21.6) | |||||||||||||||||||
Others(4)
|
49.1 | 45.3 | (3.8) | (7.7) | |||||||||||||||||||
Total Rare Hematology | 334.2 | 289.8 | (44.4) | (13.3) | |||||||||||||||||||
Hereditary Angioedema: | |||||||||||||||||||||||
TAKHZYRO | 68.3 | 86.7 | 18.4 | 27.0 | |||||||||||||||||||
FIRAZYR | 32.7 | 26.8 | (5.8) | (17.9) | |||||||||||||||||||
Others(4)
|
28.9 | 25.8 | (3.1) | (10.8) | |||||||||||||||||||
Total HAE (Hereditary Angioedema) | 129.8 | 139.3 | 9.5 | 7.3 | |||||||||||||||||||
Total Rare Diseases | 634.9 | 591.7 | (43.1) | (6.8) | |||||||||||||||||||
PDT Immunology: | |||||||||||||||||||||||
immunoglobulin | 298.7 | 334.9 | 36.2 | 12.1 | |||||||||||||||||||
albumin | 67.2 | 57.6 | (9.6) | (14.3) | |||||||||||||||||||
Others(4)
|
28.3 | 27.9 | (0.3) | (1.1) | |||||||||||||||||||
Total PDT Immunology | 394.2 | 420.4 | 26.2 | 6.7 | |||||||||||||||||||
Oncology: | |||||||||||||||||||||||
VELCADE | 118.3 | 101.1 | (17.2) | (14.5) | |||||||||||||||||||
LEUPLIN/ENANTONE | 109.0 | 95.4 | (13.7) | (12.5) | |||||||||||||||||||
NINLARO | 77.6 | 87.4 | 9.8 | 12.7 | |||||||||||||||||||
ADCETRIS | 52.7 | 59.4 | 6.8 | 12.8 | |||||||||||||||||||
ICLUSIG | 31.8 | 34.2 | 2.4 | 7.5 | |||||||||||||||||||
ALUNBRIG | 7.2 | 8.8 | 1.6 | 21.7 |
Others(4)
|
24.3 | 30.2 | 5.9 | 24.3 | |||||||||||||||||||
Total Oncology | 421.0 | 416.5 | (4.4) | (1.1) | |||||||||||||||||||
Neuroscience: | |||||||||||||||||||||||
VYVANSE/ELVANSE | 274.1 | 271.5 | (2.5) | (0.9) | |||||||||||||||||||
TRINTELLIX | 70.7 | 68.9 | (1.8) | (2.5) | |||||||||||||||||||
Others(4)
|
93.8 | 76.9 | (16.9) | (18.0) | |||||||||||||||||||
Total Neuroscience | 438.5 | 417.3 | (21.2) | (4.8) | |||||||||||||||||||
Other: | |||||||||||||||||||||||
AZILVA-F (1)
|
76.7 | 82.2 | 5.5 | 7.1 | |||||||||||||||||||
NESINA/VIPIDIA-F (1)
|
58.0 | 57.7 | (0.3) | (0.5) | |||||||||||||||||||
LOTRIGA | 31.8 | 31.8 | 0.0 | 0.0 | |||||||||||||||||||
Others (3)(4)
|
538.3 | 402.4 | (135.9) | (25.2) | |||||||||||||||||||
Total Other | 704.8 | 574.1 | (130.7) | (18.5) | |||||||||||||||||||
Total | ¥ | 3,291.2 | ¥ | 3,197.8 | ¥ | (93.4) | (2.8) | % |
For the Year Ended March 31
|
|||||||||||||||||||||||
2019 | 2020 | Change versus the previous year | |||||||||||||||||||||
(billions of yen, except for percentages) | |||||||||||||||||||||||
Gastroenterology: | |||||||||||||||||||||||
ENTYVIO | ¥ | 269.2 | ¥ | 347.2 | ¥ | 78.0 | 29.0 | % | |||||||||||||||
TAKECAB-F (1)
|
58.2 | 72.7 | 14.5 | 24.8 | |||||||||||||||||||
DEXILANT | 69.2 | 62.8 | (6.4) | (9.2) | |||||||||||||||||||
GATTEX/REVESTIVE | 12.8 | 61.8 | 49.1 | 384.7 | |||||||||||||||||||
PANTOLOC/CONTROLOC (2)
|
61.6 | 49.5 | (12.2) | (19.7) | |||||||||||||||||||
ALOFISEL | 0.0 | 0.4 | 0.3 | 728.9 | |||||||||||||||||||
Others | 68.3 | 103.5 | 35.3 | 51.7 | |||||||||||||||||||
Total Gastroenterology | 539.3 | 697.9 | 158.6 | 29.4 | |||||||||||||||||||
Rare Diseases: | |||||||||||||||||||||||
Rare Metabolic: | |||||||||||||||||||||||
ELAPRASE | 15.1 | 67.9 | 52.8 | 350.3 | |||||||||||||||||||
REPLAGAL | 11.4 | 51.3 | 39.8 | 348.1 | |||||||||||||||||||
VPRIV | 8.7 | 38.0 | 29.3 | 337.5 | |||||||||||||||||||
NATPARA/NATPAR | 7.1 | 13.6 | 6.5 | 92.2 | |||||||||||||||||||
Total Rare Metabolic | 42.3 | 170.8 | 128.5 | 303.8 | |||||||||||||||||||
Rare Hematology: | |||||||||||||||||||||||
ADVATE | 32.1 | 157.9 | 125.8 | 391.8 | |||||||||||||||||||
ADYNOVATE/ADYNOVI | 10.7 | 58.7 | 47.9 | 446.3 | |||||||||||||||||||
FEIBA | 9.6 | 51.5 | 41.9 | 434.7 | |||||||||||||||||||
Others | 14.2 | 66.2 | 52.0 | 365.2 | |||||||||||||||||||
Total Rare Hematology | 66.7 | 334.2 | 267.5 | 401.1 |
Hereditary Angioedema: | |||||||||||||||||||||||
TAKHZYRO | 9.7 | 68.3 | 58.5 | 601.8 | |||||||||||||||||||
FIRAZYR | 6.4 | 32.7 | 26.2 | 409.1 | |||||||||||||||||||
CINRYZE | 3.1 | 24.3 | 21.2 | 684.4 | |||||||||||||||||||
KALBITOR | 1.2 | 4.5 | 3.4 | 289.2 | |||||||||||||||||||
Total HAE (Hereditary Angioedema) | 20.4 | 129.8 | 109.4 | 535.9 | |||||||||||||||||||
Total Rare Diseases | 129.4 | 634.9 | 505.5 | 390.6 | |||||||||||||||||||
PDT Immunology: | |||||||||||||||||||||||
immunoglobulin | 73.5 | 298.7 | 225.2 | 306.6 | |||||||||||||||||||
albumin | 12.3 | 67.2 | 54.9 | 446.5 | |||||||||||||||||||
Others | 7.7 | 28.3 | 20.5 | 266.0 | |||||||||||||||||||
Total PDT Immunology | 93.5 | 394.2 | 300.7 | 321.7 | |||||||||||||||||||
Oncology: | |||||||||||||||||||||||
VELCADE | 127.9 | 118.3 | (9.5) | (7.5) | |||||||||||||||||||
LEUPLIN/ENANTONE | 110.1 | 109.0 | (1.0) | (0.9) | |||||||||||||||||||
NINLARO | 62.2 | 77.6 | 15.4 | 24.7 | |||||||||||||||||||
ADCETRIS | 42.9 | 52.7 | 9.8 | 22.8 | |||||||||||||||||||
ICLUSIG | 28.7 | 31.8 | 3.1 | 10.8 | |||||||||||||||||||
ALUNBRIG | 5.2 | 7.2 | 2.0 | 39.2 | |||||||||||||||||||
Others | 22.5 | 24.3 | 1.8 | 7.9 | |||||||||||||||||||
Total Oncology | 399.4 | 421.0 | 21.5 | 5.4 | |||||||||||||||||||
Neuroscience: | |||||||||||||||||||||||
VYVANSE/ELVANSE | 49.4 | 274.1 | 224.7 | 455.3 | |||||||||||||||||||
TRINTELLIX | 57.6 | 70.7 | 13.1 | 22.8 | |||||||||||||||||||
ADDERALL XR | 5.4 | 24.3 | 18.9 | 349.7 | |||||||||||||||||||
Others | 42.4 | 69.5 | 27.1 | 64.0 | |||||||||||||||||||
Total Neuroscience | 154.7 | 438.5 | 283.9 | 183.5 | |||||||||||||||||||
Other: | |||||||||||||||||||||||
AZILVA-F (1)
|
70.8 | 76.7 | 6.0 | 8.5 | |||||||||||||||||||
NESINA/VIPIDIA-F (1)
|
54.8 | 58.0 | 3.2 | 5.8 | |||||||||||||||||||
LOTRIGA | 30.9 | 31.8 | 0.9 | 2.9 | |||||||||||||||||||
Others | 624.5 | 538.3 | (86.2) | (13.8) | |||||||||||||||||||
Total Other | 780.9 | 704.8 | (76.1) | (9.8) | |||||||||||||||||||
Total | ¥ | 2,097.2 | ¥ | 3,291.2 | ¥ | 1,194.0 | 56.9 | % |
For the fiscal year ended March 31,
|
|||||||||||||||||
2019 | 2020 | 2021 | |||||||||||||||
(billions of yen)
|
|||||||||||||||||
Net cash from operating activities
|
¥ | 328.5 | ¥ | 669.8 | ¥ | 1,010.9 | |||||||||||
Net cash from (used in) investing activities
|
(2,835.7) | 292.1 | 393.5 | ||||||||||||||
Net cash from (used in) financing activities
|
2,946.2 | (1,005.2) | (1,088.4) | ||||||||||||||
Net increase (decrease) in cash and cash equivalents
|
¥ | 439.0 | ¥ | (43.3) | ¥ | 316.1 | |||||||||||
Cash and cash equivalents at the beginning of the year
|
294.5 | 702.1 | 637.6 | ||||||||||||||
Effects of exchange rate changes on cash and cash equivalents
|
(31.3) | (21.8) | 12.5 | ||||||||||||||
Net increase (decrease) in cash and cash equivalents resulting from a transfer to assets held for sale
|
(0.2) | 0.6 | — | ||||||||||||||
Cash and cash equivalents at the end of the year
|
¥ | 702.1 | ¥ | 637.6 | ¥ | 966.2 |
Rating Agency | Category | Rating | Rating Structure | |||||||||||||||||
S&P Global Ratings | Issuer credit rating/foreign currency long-term and local currency long-term | BBB+ | Fourth highest of 11 rating categories and first within the category based on modifiers (e.g. BBB+, BBB and BBB- are within the same category). | |||||||||||||||||
Issuer credit rating (short-term) | A-2 | Second highest of six rating categories | ||||||||||||||||||
Moody’s
|
Long-term issuer rating and Long-term senior unsecured rating | Baa2 | Fourth highest of nine rating categories and second highest within the category based on modifiers (e.g. Baa1, Baa2 and Baa3 are within the same category). |
Total contractual amount(1)
|
Within one year | Between one and three years | Between three and five years | More than five years | |||||||||||||||||||||||||
(billions of yen)
|
|||||||||||||||||||||||||||||
Bonds and loans: (2) (3)
|
|||||||||||||||||||||||||||||
Bonds (4)
|
¥ | 4,563.0 | ¥ | 114.7 | ¥ | 934.5 | ¥ | 724.5 | ¥ | 2,789.3 | |||||||||||||||||||
Loans (4)
|
1,150.4 | 228.0 | 187.3 | 344.5 | 390.6 | ||||||||||||||||||||||||
Purchase obligations for property, plant and equipment
|
18.9 | 18.9 | — | — | — | ||||||||||||||||||||||||
Repayment of lease liabilities | 610.3 | 50.2 | 89.0 | 79.7 | 391.3 | ||||||||||||||||||||||||
Contributions to defined benefit plans (5)
|
7.8 | 7.8 | — | — | — | ||||||||||||||||||||||||
Total (6) (7)
|
¥ | 6,350.4 | ¥ | 419.6 | ¥ | 1,210.8 | ¥ | 1,148.7 | ¥ | 3,571.2 |
Name
(Date of birth) |
Responsibilities and
status within Takeda |
Business experience
|
End of term
|
|||||||||||||||||
Christophe Weber
(November 14, 1966)
|
Representative Director, President and Chief Executive Officer
(“CEO”) |
Christophe Weber is President and CEO of Takeda. He joined Takeda in April 2014 as Chief Operating Officer and Corporate Officer, was named President and Representative Director in June 2014 and was subsequently appointed Chief Executive Officer in April 2015. Since September 2020, Mr. Weber has also served as Head of Global Business of Takeda Pharmaceuticals U.S.A., Inc. Prior to joining Takeda, Mr. Weber held positions of increasing responsibility at GlaxoSmithKline, including President and General Manager at GlaxoSmithKline Vaccines, Chief Executive Officer of GlaxoSmithKline Biologicals SA in Belgium, and member of the GlaxoSmithKline global Corporate Executive Team. From 2008 to 2010, Mr. Weber served as Asia Pacific SVP and Regional Director at GlaxoSmithKline Asia Pacific in Singapore.
|
Note 1 | |||||||||||||||||
Costa Saroukos
(April 15, 1971)
|
Director and Chief Financial Officer (“CFO”)
|
Costa Saroukos has been Takeda’s Chief Financial Officer since April 2018. He was appointed as Corporate Officer in April 2018 and Director in June 2019. Mr. Saroukos has over 20 years of experience in both the private and public sectors, having held a number of finance leadership positions with financial responsibility for businesses in over 100 countries across Asia-Pacific, Europe, Africa and the Middle East. Mr. Saroukos has been with Takeda since May 2015, as CFO of the Europe and Canada business unit, significantly contributing to the transformation of the business unit towards a specialty healthcare provider. Prior to joining Takeda, Mr. Saroukos was at Allergan as Head of Finance and Business Development for the Asia-Pacific region, including China and Japan. He was also Finance Director for Greater China and Japan. Previously, he spent 13 years at Merck & Co. in roles of increasing responsibility, including Executive Finance Director for EEMEA (Eastern Europe, Middle East and Africa), Finance Director of South Korea and Head of Internal Audit Asia Pacific and Global Joint Ventures.
|
Note 1
|
|||||||||||||||||
Masato Iwasaki, Ph.D.
(November 6, 1958)
|
Representative Director, Japan General Affairs
|
Masato Iwasaki is Representative Director, Japan General Affairs of Takeda. He joined Takeda in 1985 and had an extensive career in roles of increasing responsibility in sales and marketing under the Pharmaceutical Marketing Division. In 2003, Dr. Iwasaki was appointed Manager of Strategic Product Planning and Project Leader for the Cardiovascular and Metabolic franchise. He was appointed Senior Vice President of the Strategic Product Planning department in 2008. In 2010, Dr. Iwasaki was named Corporate Officer. Dr. Iwasaki has been a Director and Member of our board of directors since 2012 and was named President of the Japan Pharma Business Unit in 2015. Dr. Iwasaki was named Director, Japan General Affairs in April 2021 and named Representative Director in June 2021.
|
Note 1 |
Name
(Date of birth) |
Responsibilities and
status within Takeda |
Business experience
|
End of term
|
|||||||||||||||||
Andrew S. Plump, M.D., Ph.D.
(October 13, 1965)
|
Director and President, Research and Development | Andrew S. Plump, MD., Ph.D., is the President of Research and Development at Takeda. Dr. Plump joined Takeda as Chief Medical and Scientific Officer (“CMSO”) in 2015. In his position, he leads our global research and development organization, where he provides strategic direction and oversight. Prior to joining Takeda, Dr. Plump served as Senior Vice President, Research and Translational Medicine, Deputy to the President of research and development at Sanofi, where he was responsible for global research and translational medicine across all therapeutic areas. Dr. Plump also spent more than 10 years at Merck in a Clinical Pharmacology group, working on programs in neurodegeneration, immunology, metabolism and infectious diseases. | Note 1 | |||||||||||||||||
Olivier Bohuon
(January 3, 1959)
|
External Director |
Olivier Bohuon has been an External Director with Takeda since January 2019. Prior to his appointment, Mr. Bohuon was an External Director of Shire. Mr. Bohuon currently also holds the position of External Director and Chairman at Majorelle International, External Director at Virbac SA, External Director at AlgoTherapeutix SAS and External Director at Reckitt Benckiser Group plc. Mr. Bohuon has previously served as External Director and Chairman at LEO Pharma A/S, Chief Executive Officer of Smith & Nephew plc, Chief Executive Officer and President of Pierre Fabre Group SA and as President of Abbott Pharmaceuticals; a division of US-based Abbott Laboratories. He has also held diverse commercial leadership positions at GlaxoSmithKline and its predecessor companies in France.
|
Note 1 | |||||||||||||||||
Ian Clark
(August 27, 1960)
|
External Director |
Ian Clark has been an External Director with Takeda since January 2019. Prior to his appointment, Mr. Clark was an External Director of Shire plc. He also currently holds External Directorships at Agios Pharmaceuticals, Inc., Corvus Pharmaceuticals, Inc., Guardant Health, Inc., AVROBIO Inc, and Olema Pharmaceuticals, Inc. Mr. Clark served as CEO and Director of Genentech Inc. (part of the Roche Group) and Head of North American Commercial Operations for Roche until 2016. From 2003 to 2010 he held the positions of Head of Global Product Strategy and Chief Marketing Officer, Executive Vice President—Commercial Operations and Senior Vice President and General Manager—BioOncology at Genentech.
|
Note 1 | |||||||||||||||||
Yoshiaki Fujimori (July 3, 1951) | External Director |
Yoshiaki Fujimori has served as External Director of Takeda since June 2016. Mr. Fujimori currently also serves as Senior Executive Advisor of CVC Asia Pacific (Japan) Kabushiki Kaisha, External Director of Oracle Corporation Japan, External Director of Riraku K.K. and External Director of Shiseido Company, Limited. He previously served as External Director of Tokyo Electric Power Company, Incorporated (currently Tokyo Electric Power Company Holdings, Incorporated), External Director of Toshiba Corporation and in a number of senior leadership positions within the LIXIL Group, including Representative Director, Chairman and CEO of LIXIL Corporation. Mr. Fujimori has also served in a number of senior positions in the General Electric Group, including Chairman of GE Japan Corporation and Chairman, President and CEO of General Electric Japan Ltd.
|
Note 1 | |||||||||||||||||
Steven Gillis, PhD
(April 25, 1953)
|
External Director |
Dr. Steven Gillis has been an External Director with Takeda since January 2019. Prior to his appointment, Dr. Gillis was an External Director of Shire plc. He also currently holds the positions of Managing Director at ARCH Venture Partners, External Director and Chairman of Codiak BioSciences, Inc., External Director of Homology Medicines, Inc. and External Director and Chairman, VBI Vaccines, Inc. Dr. Gillis was a founder and Director of Corixa Corporation, acquired by GlaxoSmithKline in 2005, and before that a founder and Director of Immunex Corporation.
|
Note 1 |
Name
(Date of birth) |
Responsibilities and
status within Takeda |
Business experience
|
End of term
|
|||||||||||||||||
Masahiro Sakane
(January 7, 1941)
|
External Director | Masahiro Sakane has served as External Director of Takeda since June 2014 and was appointed Chair of the Board of Directors meeting in June 2017. Mr. Sakane currently also serves as Advisor of Komatsu Ltd., and External Director of Kajima Corporation. Mr. Sakane started his career at Komatsu Ltd. in April 1963. In the Komatsu group, he served in several senior leadership positions including Chairman of the Board and Representative Director and President and Representative Director of Komatsu Ltd. and Chief Operating Officer (“COO”) of Komatsu Dresser Company (currently Komatsu America Corp.). Mr. Sakane has also served as External Director of Nomura Holdings, Inc., External Director of Nomura Securities Co., Ltd., External Director of Tokyo Electron Limited, External Director of Asahi Glass Company, Ltd. and Vice Chairman of Keidanren (Japan Business Federation). | Note 1 | |||||||||||||||||
Toshiyuki Shiga
(September 16, 1953)
|
External Director |
Toshiyuki Shiga has served as External Director of Takeda since June 2016. Mr. Shiga currently also serves as Chairman and CEO of INCJ, Ltd and External Director of Dynamic Map Platform Co., Ltd. Mr. Shiga started his career at Nissan Motor Co., Ltd. in April 1976. At Nissan Motor Co., Ltd., he served in a number of leadership positions including Vice Chairman, Chief Operating Officer and Senior Vice President (Officer). He has also served as Chairman of Japanese Automobile Manufacturers Association, Inc.Vice Chairman of KEIZAI DOYUKAI (Japan Association of Corporate Executives) and Chairman and CEO of Innovation Network Corporation of Japan.
|
Note 1 | |||||||||||||||||
Jean-Luc Butel
(November 8, 1956) |
External Director |
Jean-Luc Butel served as External Director and member of the Audit and Supervisory Committee of Takeda from June 2016 to June 2019. He was appointed External Director who is not a member of the Audit and Supervisory Committee of Takeda in June 2019. He currently also serves as Global Healthcare Advisor, President of K8 Global Pte. Ltd., External Director of Accelerate Technologies Pte. Ltd., External Director of Varian Medical Systems, Inc., External Director of SGInnovate and External Director of Novo Holdings A/S. Mr. Butel previously served as President, International, Corporate Vice President and Operating Committee Member of Baxter International Inc. and has held leadership positions at Medtronic, Inc., Johnson & Johnson, Becton, Dickinson and Company and Nippon Becton Dickinson Company, Ltd.
|
Note 1 | |||||||||||||||||
Shiro Kuniya
(February 22, 1957)
|
External Director
|
Shiro Kuniya served as External Director and Head of the Audit and Supervisory Committee of Takeda from June 2016 to June 2019. He was appointed External Director who is not a member of the Audit and Supervisory Committee of Takeda in June 2019. He currently also serves as Managing Partner of Oh-Ebashi LPC & Partners, External Director of NEXON Co., Ltd. and External Director of TOA CORPORATION. Mr. Kuniya was registered as an attorney-at-law (Osaka Bar Association) and joined Oh-Ebashi Law Offices in April 1982 and was also admitted to practice law in New York State in the United States in May 1987. He has also previously served as our Outside Corporate Auditor as well as Chairman of the Inter-Pacific Bar Association, Outside Corporate Auditor of NIDEC CORPORATION, Outside Corporate Auditor of Sunstar Inc, External Director of EBARA CORPORATION and External Director of Sony Financial Holdings Inc.
|
Note 1 |
Name
(Date of birth) |
Responsibilities and
status within Takeda |
Business experience
|
End of term
|
|||||||||||||||||
Koji Hatsukawa
(September 25, 1951)
|
External Director (Head of Audit and Supervisory Committee) | Koji Hatsukawa has served as External Director and member of the Audit and Supervisory Committee of Takeda since June 2016. He was appointed Head of Audit and Supervisory Committee in June 2019. He currently also serves as Outside Audit and Supervisory Board Member of Fujitsu Limited. Mr. Hatsukawa started his career at Price Waterhouse accounting office in March 1974. Mr. Hatsukawa has previously served CEO of PricewaterhouseCoopers Arata and has held leadership positions at ChuoAoyama PricewaterhouseCoopers and Aoyama Audit Corporation. In addition, he has also served as Outside Audit and Supervisory Board Member of Accordia Golf co., Ltd. as well as Audit and Supervisory Board Member of The Norinchukin Bank. | Note 2 | |||||||||||||||||
Emiko Higashi
(November 6, 1958)
|
External Director (Audit and Supervisory Committee Member) |
Emiko Higashi served as External Director who is not a member of the Audit and Supervisory Committee of Takeda from June 2016 to June 2019. She was appointed External Director who is a member of the Audit and Supervisory Committee of Takeda in June 2019. She currently also serves as Managing Director of Tomon Partners, LLC, External Director of KLA Corporation, External Director of Rambus Inc, and External Director of One Equity Partners Open Water I Corporation. Ms. Higashi previously served as External Director of MetLife Insurance K.K., External Director of InvenSense Inc., External Director of Sanken Electric Co., Ltd., CEO of Gilo Ventures, LLC, Managing Director of Investment Banking, Merrill Lynch & Co. and Director of Wasserstein Perella & Co., Inc.
|
Note 2 | |||||||||||||||||
Michel Orsinger
(September 15, 1957)
|
External Director (Audit and Supervisory Committee Member) | Michel Orsinger has served as External Director who is not a member of the Audit and Supervisory Committee of Takeda from June 2016 to June 2019. He was appointed External Director who is a member of the Audit and Supervisory Committee of Takeda in June 2019. He previously served as a Member of Global Management Team of Johnson & Johnson, Worldwide Chairman, Global Orthopedics Group of DePuy Synthes Companies of Johnson & Johnson and President and Chief Executive Officer and Chief Operating Officer of Synthes, Inc. (currently Johnson & Johnson). He has also held several leadership positions at Novartis AG, including Chief Executive Officer and President of OTC Division Worldwide, Consumer Health; President of Global Medical Nutrition, Consumer Health; and Regional President of Europe, Middle East and Africa, Consumer Health. | Note 2 | |||||||||||||||||
Masami Iijima
(September 23, 1950)
|
External Director (Audit and Supervisory Committee Member)
|
Masami Iijima was appointed External Director who is a member of the Audit and Supervisory Committee of Takeda in June 2021. Mr. Iijima currently also serves as Counselor of Mitsui & Co., Ltd., External Director of Ricoh Company, Ltd., External Director of SoftBank Group Corp., Counsellor at Bank of Japan and External Director of Isetan Mitsukoshi Holdings Ltd. Mr. Iijima started his career at Mitsui & Co., Ltd. in April 1974. At Mitsui & Co., Ltd., he served in several senior leadership positions including Chairman of the Board of Directors and Representative Director, President and Chief Executive Officer.
|
Note 2 |
Name
(Date of birth) |
Responsibilities and
status within Takeda |
Business experience
|
||||||||||||
Marcello Agosti
(June 2, 1971)
|
Global Business Development Officer |
In January 2019, Marcello Agosti became Global Business Development Officer. Mr. Agosti is responsible for Takeda’s Business Development activities, including mergers and acquisitions and corporate development.
Mr. Agosti has led the Shire Acquisition and several other acquisitions for Takeda, including ARIAD Pharmaceuticals, transforming Takeda’s global oncology portfolio and TiGenix, and strengthening the company’s GI leadership position. Mr. Agosti has also led Takeda’s Global Commercial organization since 2015, which included the successful launch of Takeda’s first global brand, ENTYVIO, now approved in more than 60 countries. He has also held a number of leadership positions in Europe as Country Manager in France and in Italy and as Area Head of Southern and Eastern Europe. Prior to joining Takeda, Mr. Agosti worked in business development at Novartis in the U.K. and Switzerland and was also a consultant at McKinsey & Co. |
||||||||||||
Teresa Bitetti
(September 21, 1962)
|
President, Global Oncology Business Unit |
In April 2019, Teresa Bitetti joined Takeda as President of the Global Oncology Business Unit. She is responsible for oncology business activities.
Prior to joining Takeda, Ms. Bitetti was the Senior Vice President, Head of Worldwide Oncology Commercialization at Bristol-Myers Squibb. In this role, Ms. Bitetti significantly enhanced the long term strategic direction of the immuno-oncology portfolio. In addition, she further enhanced the model of collaboration with the research and development team to ensure the long term success of its marketed and pipeline Oncology products. Some of her key leadership roles included, Senior Vice President and Head of U.S. Oncology where she was responsible for the launch of Opdivo, President and GM of BMS Canada, and Worldwide Head of the BMS Virology business. Prior to joining Bristol-Myers Squibb, Ms. Bitetti held various roles of increasing responsibility at Mobil Oil Corporation where she was part of the Capital Markets Group and was responsible for the investment of Mobil’s worldwide pension assets. |
||||||||||||
Lauren Duprey
(May 13, 1984)
|
Chief Human Resources Officer
|
Lauren Duprey is the Chief Human Resources Officer of Takeda Pharmaceutical Company Ltd. with responsibility for delivering an exceptional people experience across the globe. She joined Takeda in August 2019 as Head of Human Resources (HR) for the U.S. Business Unit, Global Product & Launch Strategy and the U.S. People Advisory Group. Since joining Takeda, Ms. Duprey has implemented a transformation of HR in the U.S., including a new operating model, structure, capabilities and technology. In addition, she built a new diversity, equity and inclusion (DE&I) organization which has shaped a leading-edge DE&I strategy for Takeda in the U.S.
Prior to joining Takeda, Ms. Duprey served as Head of HR, U.S. Organization & Worldwide Medical at Biogen where she developed and drove the talent and organization strategy and served as a trusted advisor in regards to key business, talent and organizational decisions. She has held various HR roles at companies such as General Electric and began her career in management consulting at Clarion Healthcare focused on biopharma commercialization.
Ms. Duprey holds a bachelor’s degree in biology from Harvard University and an MBA from Massachusetts Institute of Technology (MIT) Sloan School of Management.
|
Name
(Date of birth) |
Responsibilities and
status within Takeda |
Business experience
|
||||||||||||
Milano Furuta
(February 26, 1978) |
President, Japan Pharma Business Unit
|
Milano Furuta is President, Japan Pharma Business Unit of Takeda Pharmaceutical Company Limited.
Mr. Furuta joined Takeda in 2010 and has worked on various projects in corporate strategy, corporate development, and post-merger integration in Japan and Switzerland. He managed the Diabetes Business Unit in Mexico and served as General Manager in Sweden, leading the launch of new products in the areas of oncology, diabetes, cardiovascular and metabolism, while optimizing commercial organizations. He went on to serve as Corporate Strategy Officer and Chief of Staff in Japan for two years before his appointment to his current role.
Prior to joining Takeda, Mr. Furuta worked as an equity research analyst at an investment management firm in the United States. He began his career in banking and private equity investment in Japan, where he was involved with several types of financial transactions, including leveraged buyouts and debt restructuring.
Mr. Furuta holds an MBA from The Wharton School, University of Pennsylvania and a BA in international affairs from Hitotsubashi University, Japan.
|
||||||||||||
Gerard Greco, Ph.D.
(February 8, 1962) |
Global Quality Officer |
In September 2014, Dr. Gerard Greco joined Takeda as Global Quality Officer. Dr. Greco has more than 35 years of experience in quality leadership roles in the pharmaceutical industry.
At Takeda, Dr. Greco has introduced key transformations by creating a Global Quality Organization that aligns the quality units and establishes consistent quality systems and programs across the network. Prior to joining Takeda, Dr. Greco held positions of increasing responsibility at Johnson & Johnson, Wyeth Pharmaceuticals, Pfizer Inc. and Teva Pharmaceuticals, where he served as Senior Vice President of Global Quality Operations. |
||||||||||||
Takako Ohyabu
(August 26, 1979) |
Chief Global Corporate Affairs Officer |
Takako Ohyabu is Chief Global Corporate Affairs Officer overseeing global corporate communications, global corporate social responsibility, global public affairs, global security and crisis management, and sustainability for Takeda Pharmaceutical Company Limited. She joined the company in November 2019 as Chief Communications and Public Affairs Officer Designate.
Prior to joining Takeda, Ms. Ohyabu led the Global Corporate Communications function at Nissan Motor Corporation. Before that she was with General Electric Company managing corporate communications for a variety of industries and building the corporate brand in both developed and emerging markets.
Ms. Ohyabu holds a master’s degree in Public Administration from Columbia University’s School of International and Public Affairs and a bachelor’s degree in Political Science from the International Christian University in Japan.
|
||||||||||||
Julie Kim
(June 6, 1970) |
President, Plasma-Derived Therapies Business Unit
|
In January 2019, Julie Kim joined Takeda as President of the Plasma-Derived Therapies Business Unit and serves as a member of the Takeda Executive Team. She is responsible for building a sustainable, high growth business focused on meeting the large and growing global demand for plasma-derived products.
Previously at Shire/Baxalta/Baxter, Julie has held a diverse number of senior roles. She led the access function for the entire Shire portfolio outside of the US, ran Global Franchises for Shire Hematology and Baxter Immunology, managed country organizations as North/South Europe Cluster Head for Baxalta Immunology and General Manager for Baxter UK/Ireland, among other roles. Julie started her career as a consultant in the U.S. healthcare space. Julie is a member of the Global Board for the Plasma Protein Therapeutics Association (“PPTA”, a plasma industry organization). She is also a member of the Board for the Jeffrey Modell World Immunodeficiency Network, part of the Jeffrey Modell Foundation. |
Name
(Date of birth) |
Responsibilities and
status within Takeda |
Business experience
|
||||||||||||
Mwana Lugogo
(January 30, 1970) |
Chief Ethics and Compliance Officer |
In October 2014, Mwana Lugogo became Takeda’s Chief Ethics & Compliance Officer. Having joined Takeda in 2012, she initially established the Compliance function for our Growth & Emerging Markets Business Unit.
In 2015, Ms. Lugogo was appointed to lead the newly-created Global Compliance function. In this role, she is the custodian of Takeda’s Global Code of Conduct and is responsible for the global ethics & compliance program. She also ensures that ethical and reputational risks related to Takeda’s business are identified and addressed. Before joining Takeda, Ms. Lugogo worked as an attorney in private practice in the U.S., U.K. and Central Asia for six years. In 2002, she moved into the corporate world with Interbrew in Belgium. She moved to Switzerland in 2009, when she joined the Legal department at Baxter Healthcare, responsible for Central and Eastern Europe, and Emerging Markets. |
||||||||||||
Ricardo Marek
(May 30, 1970) |
President, Growth and Emerging Markets Business Unit
|
Ricardo Marek is President of Growth and Emerging Markets (“GEM”) Business Unit.
Mr. Marek has over 25 years of experience in various industries and leadership roles. He has been with Takeda for eight years and over this time he simultaneously held the roles of Area Head for Latin America (“LATAM”) since 2014, President for Brazil since 2013. Prior to that, he was CFO of Brazil.
He led the realignment and restructuring of the LATAM area, positioning it as one of the top performers across EM BU, and Takeda Brazil as one of the top 10 pharmaceutical companies in the country. He also secured a number of acquisitions as well as launched the Oncology business in the region for Takeda’s potentially life-saving and life-transforming medicines. Under his leadership, Takeda was recognized for the first time as a top employer in all seven countries across the LATAM region, and also received several other HR awards, such as Great Place to Work.
Before joining Takeda in 2011, he was CFO for Organon International in the U.S., and Managing Director and Vice President Finance for the Akzo Nobel Group in Brazil. He also has experience in other industries such as chemicals and aerospace.
|
||||||||||||
Yoshihiro Nakagawa
(July 26, 1960) |
Global General Counsel |
In October 2014, Yoshihiro Nakagawa was appointed Corporate Officer and Global General Counsel of Takeda. He is responsible for the company’s global legal and intellectual property organizations.
Mr. Nakagawa joined the company in 1983. At that time, he served in varying roles of responsibility including reviewing, negotiating and drafting intellectual property and technology-related licensing agreements as a member of the Patent & Trademark Department. In 1995, he moved to the Legal Department, then spent more than two years in London as Company Secretary for Takeda Europe Holdings. Prior to his current appointment, Mr. Nakagawa served as Senior Vice President of the Legal Department at Takeda headquarters in Japan. |
||||||||||||
Giles Platford
(April 26, 1978) |
President, Europe and Canada Business Unit |
Giles Platford is President of Europe and Canada Business Unit for Takeda.
A seasoned industry leader with over 15 years of pharmaceutical experience, Giles was formerly President of Emerging Markets for Takeda, where he oversaw the launch of Takeda’s innovative pipeline across the region, and led the design and roll-out of Takeda’s global access to medicines program. Previously, Giles headed the Middle East, Turkey and Africa region where he strengthened controls and compliance whilst re-engineering the business for growth. He also held various leadership positions including General Manager Brazil, where he transformed Takeda into a top 10 pharma industry player, being externally recognized for the first time as one of the country’s top employers and best companies to work for. Before joining Takeda in 2009, Giles spent eight years in Asia Pacific, where he assumed a number of business development, commercial and general Management roles. |
Name
(Date of birth) |
Responsibilities and
status within Takeda |
Business experience
|
||||||||||||
Koki Sato
(December 10, 1980)
|
Corporate Strategy Officer and Chief of Staff
|
Koki Sato is the Corporate Strategy Officer and Chief of Staff of Takeda Pharmaceutical Company Limited.
Mr. Sato joined Takeda in 2003 and has been increasing responsibilities throughout his career with Takeda, spanning many countries and multiple functions. After he took a regional role in Emerging Markets in 2012, he has held several leadership roles, such as Country Manager of Belarus, General Manager of Ukraine cluster, and General Manager of India before taking his current role.
Mr. Sato holds a bachelor’s degree in Economics from School of Political Science & Economics, Waseda University in Tokyo.
|
||||||||||||
Ramona Sequeira
(November 21, 1965) |
President, United States Business Unit and Global Portfolio Commercialization |
Ramona Sequeira is the President of United States Business Unit and leads Takeda’s Portfolio Commercialization globally. Ms.Sequeira joined Takeda in 2015.
Through her work with Takeda and prior to that with Eli Lilly, Ms. Sequeira has over 25 years of experience in the pharmaceutical industry. She has led businesses in Canada, Europe and the U.S. Ms. Sequeira is committed to the industry’s role in shaping a positive environment that rewards pharmaceutical innovation and ensures patients have access to innovative medicines that can help them have better health. She is a member of the PhRMA Board of Directors, and was recently appointed Treasurer of the Board. Prior to that, she served as Chair of PhRMA’s State Committee. Prior to Takeda, Ms. Sequeira received a B.Sc. with honors in molecular genetics and molecular biology from the University of Toronto, and later received an MBA from McMaster University in Canada. |
||||||||||||
Rajeev Venkayya, M.D.
(March 6, 1967) |
President, Global Vaccine Business Unit |
Dr. Rajeev Venkayya serves as President of the Vaccine Business Unit. He joined Takeda in 2012 to launch the global vaccine business, building upon a longstanding business in Japan. Since then, he has formed a global organization and established a high-impact vaccine pipeline that includes promising late-stage candidates for dengue and norovirus, gained through the acquisitions of LigoCyte and Inviragen Inc. He concurrently serves on the boards of two NGOs: CEPI (Coalition for Epidemic Preparedness Innovations), and IAVI (International AIDS Vaccine Initiative).
Prior to Takeda, Dr. Venkayya served as Director of Vaccine Delivery in the Global Health Program at the Bill & Melinda Gates Foundation, where he was responsible for the Foundation’s efforts in polio eradication and new vaccine introduction, and a grant portfolio of 500 million USD/year. While at the foundation, he served on the board of the Global Alliance for Vaccines and Immunization (“GAVI”).
Dr. Venkayya was previously the Special Assistant to the President for Biodefense at the White House. In this capacity, he oversaw U. S. preparedness for bioterrorism and biological threats, and was responsible for the development and implementation of the National Strategy for Pandemic Influenza. He first came to Washington though the non-partisan White House Fellowship program in 2002.
Dr. Venkayya was trained in pulmonary and critical care medicine and served as an Assistant Professor of Medicine in the Division of Pulmonary and Critical Care Medicine at the University of California, San Francisco. He also served as co-director of the Medical Intensive Care Unit and Director of the High-Risk Asthma Clinic at San Francisco General Hospital.
|
||||||||||||
Thomas Wozniewski,
Ph.D. (July 26, 1962) |
Global Manufacturing and Supply Officer |
In July 2014, Thomas Wozniewski, Ph.D. joined Takeda as Global Manufacturing and Supply Officer. He has more than 20 years of experience in the pharmaceutical industry.
Dr. Wozniewski joined Takeda from Bayer Healthcare Switzerland, where he was Head of Product Supply Consumer Care. In this role, he was responsible for the end-to-end supply chain for all Bayer global OTC products. Prior to this, he served as Head of Global Pharmaceuticals Product Supply at Bayer Healthcare AG and Schering AG in Germany.
While at Schering AG, he was also Head of Global Quality, Environment and Safety, leading the development and implementation of an Integrated Management System for the company. Dr. Wozniewski also worked at Boehringer Ingelheim, where he held several positions in quality and production.
|
Name
(Position) |
Total consolidated compensation (millions of yen)
|
Company | Amount of consolidated compensation by type (millions of yen) | |||||||||||||||||||||||||||||||||||||||||
Base compensation
|
Performance-based compensation | Non-monetary compensation | Other | |||||||||||||||||||||||||||||||||||||||||
Annual bonus |
Performance Shares(1)(2)
|
Restricted stock(1)
|
||||||||||||||||||||||||||||||||||||||||||
Christophe Weber (Director) | ¥ | 1,874 | Takeda |
¥ 246(4)
|
¥ | 247 |
¥ 900(5)
|
¥ 379(5)
|
¥ | — | ||||||||||||||||||||||||||||||||||
Takeda Pharmaceuticals U.S.A., Inc.(3)
|
21 | 81 | — | — | — | |||||||||||||||||||||||||||||||||||||||
Masato Iwasaki (Director) | 289 |
Takeda
(Director portion) |
35 | 49 |
107(7)
|
37(7)
|
— | |||||||||||||||||||||||||||||||||||||
Takeda
(Employee portion)(6)
|
27 | 32 | — | — | — | |||||||||||||||||||||||||||||||||||||||
Andrew S. Plump (Director) | 911 | Takeda | 12 | — | — | — | — | |||||||||||||||||||||||||||||||||||||
Takeda Pharmaceuticals International, Inc.(8)
|
122 | 172 |
421(9)
|
143(9)
|
42(10)
|
|||||||||||||||||||||||||||||||||||||||
Costa Saroukos (Director) | 626 |
Takeda
(Director portion) |
200(11)
|
153 |
187(12)
|
85(12)
|
— | |||||||||||||||||||||||||||||||||||||
Yasuhiko Yamanaka
(Director who is an Audit and Supervisory Committee Member)(13)
|
50 | Takeda | 38 | — | — |
13(14)
|
— |
Name
(Position) |
Total consolidated compensation (millions of yen)
|
Company | Amount of consolidated compensation by type (millions of yen) | |||||||||||||||||||||||||||||||||||||||||
Base compensation
|
Performance-based compensation | Non-monetary compensation | Other | |||||||||||||||||||||||||||||||||||||||||
Annual bonus | Performance Shares |
Restricted stock(1)
|
||||||||||||||||||||||||||||||||||||||||||
Masahiro Sakane
(Director) |
¥ | 43 | Takeda | ¥ | 24 | ¥ | — | ¥ | — | ¥ | 19 | ¥ | — | |||||||||||||||||||||||||||||||
Olivier Bohuon
(Director) |
38 | Takeda | 19 | — | — | 19 | — | |||||||||||||||||||||||||||||||||||||
Jean-Luc Butel
(Director) |
38 | Takeda | 19 | — | — | 19 | — | |||||||||||||||||||||||||||||||||||||
Ian Clark
(Director) |
38 | Takeda | 19 | — | — | 19 | — | |||||||||||||||||||||||||||||||||||||
Yoshiaki Fujimori
(Director) |
38 | Takeda | 19 | — | — | 19 | — | |||||||||||||||||||||||||||||||||||||
Steven Gillis
(Director) |
38 | Takeda | 19 | — | — | 19 | — | |||||||||||||||||||||||||||||||||||||
Shiro Kuniya
(Director) |
38 | Takeda | 19 | — | — | 19 | — | |||||||||||||||||||||||||||||||||||||
Toshiyuki Shiga
(Director) |
38 | Takeda | 19 | — | — | 19 | — | |||||||||||||||||||||||||||||||||||||
Koji Hatsukawa
(Director who is an Audit and Supervisory Committee Member) |
41 | Takeda | 22 | — | — | 19 | — | |||||||||||||||||||||||||||||||||||||
Emiko Higashi
(Director who is an Audit and Supervisory Committee Member) |
43 | Takeda | 24 | — | — | 19 | — | |||||||||||||||||||||||||||||||||||||
Michel Orsinger
(Director who is an Audit and Supervisory Committee Member) |
41 | Takeda | 22 | — | — | 19 | — |
Name
|
Company | Severance Payment | Other Benefits | |||||||||||||||||
Christophe Weber | Takeda |
Sum of (i) 100% of annual base salary, (ii) 100% of annual target bonus and (iii) 100% of annual target value of Long-Term Incentive payments, subject to the approval of the shareholders’ meeting, to the extent required by applicable law and to the extent permitted in light of fiduciary duty and the duty of loyalty of the directors of Takeda
|
Certain repatriation-related benefits, subject to the approval of the shareholders’ meeting, to the extent required by applicable law and to the extent permitted in light of fiduciary duty and the duty of loyalty of the directors of Takeda
|
|||||||||||||||||
Takeda Pharmaceuticals U.S.A, Inc. |
Sum of (i) 100% of annual base salary and (ii) 100% of annual target value of Short-Term Incentive payments, subject to the approval of the shareholders’ meeting, to the extent required by applicable law and to the extent permitted in light of fiduciary duty and the duty of loyalty of the directors of Takeda
|
None |
Costa Saroukos | Takeda |
Sum of (i) 100% of annual base salary, (ii) 100% of annual target bonus and (iii) 100% of annual target value of Long-Term Incentive payments, subject to the approval of the shareholders’ meeting, to the extent required by applicable law and to the extent permitted in light of fiduciary duty and the duty of loyalty of the directors of Takeda
|
Certain repatriation-related benefits, subject to the approval of the shareholders’ meeting, to the extent required by applicable law and to the extent permitted in light of fiduciary duty and the duty of loyalty of the directors of Takeda
|
|||||||||||||||||
Andrew S. Plump | Takeda Pharmaceuticals International, Inc. | Sum of (i) 12 months of current monthly base salary (24 months in the case where Mr. Plump voluntarily terminates his employment for good reason) and (ii) 100% of annual target level bonus under the Short-Term Incentive Program | Certain health insurance benefits | |||||||||||||||||
Japan
|
United States
|
Europe and Canada
|
Other
|
Total
|
||||||||||||||||||||||
5,586 | 19,139 | 13,867 | 8,507 | 47,099 |
Name | Number of shares held (number of shares scheduled to be issued pursuant to Board Incentive Plan (“BIP”) and Employee Stock Ownership Plan (“ESOP”)) | |||||||
Christophe Weber | 355,500 | |||||||
(635,587) | ||||||||
Costa Saroukos | 21,200 | |||||||
(164,449) | ||||||||
Masato Iwasaki | 46,096 | |||||||
(70,728) | ||||||||
Andrew Plump | — | |||||||
(157,863) | ||||||||
Olivier Bohuon | — | |||||||
(12,458) | ||||||||
Ian Clark | — | |||||||
(12,458) |
Name | Number of shares held (number of shares scheduled to be issued pursuant to Board Incentive Plan (“BIP”) and Employee Stock Ownership Plan (“ESOP”)) | |||||||
Yoshiaki Fujimori | 4,400 | |||||||
(14,620) | ||||||||
Steven Gillis | — | |||||||
(12,458) | ||||||||
Masahiro Sakane | 900 | |||||||
(14,620) | ||||||||
Toshiyuki Shiga | 3,600 | |||||||
(14,620) | ||||||||
Jean-Luc Butel | — | |||||||
(16,634) | ||||||||
Shiro Kuniya | 2,100 | |||||||
(14,620) | ||||||||
Koji Hatsukawa | 2,400 | |||||||
(14,620) | ||||||||
Emiko Higashi | — | |||||||
(16,634) | ||||||||
Michel Orsinger | — | |||||||
(16,634) | ||||||||
Masami Iijima | — | |||||||
— | ||||||||
Total | 436,196 | |||||||
(1,189,003) |
Shareholder |
Number of shares
held of record |
Percentage of
issued shares(1) |
||||||||||||
(thousands, except percentages) | ||||||||||||||
The Master Trust Bank of Japan, Ltd. (Trust account) | 150,521 | 9.55 | % | |||||||||||
Custody Bank of Japan, Ltd. (Trust account) | 84,159 | 5.34 | ||||||||||||
The Bank of New York Mellon as depositary bank for depositary receipt holders
(Standing proxy: Sumitomo Mitsui Banking Corporation) |
78,566 | 4.98 | ||||||||||||
Nippon Life Insurance Company (Standing proxy: The Master Trust Bank of Japan, Ltd.) | 35,360 | 2.24 | ||||||||||||
Custody Bank of Japan, Ltd. (Trust account 5) | 25,510 | 1.62 | ||||||||||||
State Street Bank West Client-Treaty 505234
(Standing proxy: Settlement & Clearing Services Department, Mizuho Bank, Ltd.) |
25,343 | 1.61 | ||||||||||||
Custody Bank of Japan, Ltd. (Trust account 6) | 22,618 | 1.43 | ||||||||||||
JP Morgan Chase Bank 385632
(Standing proxy: Settlement & Clearing Services Department, Mizuho Bank, Ltd.) |
21,669 | 1.37 | ||||||||||||
Custody Bank of Japan, Ltd. (Trust account 7) | 20,368 | 1.29 | ||||||||||||
Custody Bank of Japan, Ltd. (Trust account 1) | 20,305 | 1.29 | ||||||||||||
Total | 484,418 | 30.73 | % |
Dividends declared and paid |
JPY (billions)
Total dividends |
Dividends per share JPY | Record date | Effective date | ||||||||||||||||||||||
April 1, 2018, to March 31, 2019 | ||||||||||||||||||||||||||
Q1 2018 | ¥ | 71.5 | ¥ | 90.00 | March 31, 2018 | June 29, 2018 | ||||||||||||||||||||
Q3 2018 | 71.5 | 90.00 | September 30, 2018 | December 3, 2018 | ||||||||||||||||||||||
April 1, 2019, to March 31, 2020 | ||||||||||||||||||||||||||
Q1 2019 | 140.8 | 90.00 | March 31, 2019 | June 28, 2019 | ||||||||||||||||||||||
Q3 2019 | 141.9 | 90.00 | September 30, 2019 | December 2, 2019 | ||||||||||||||||||||||
April 1, 2020, to March 31, 2021 | ||||||||||||||||||||||||||
Q1 2020 | 141.9 | 90.00 | March 31, 2020 | June 25, 2020 | ||||||||||||||||||||||
Q3 2020 | 141.9 | 90.00 | September 30, 2020 | December 1, 2020 |
Dividends declared |
JPY (billions)
Total dividends |
Dividends per share JPY | Record date | Effective date | ||||||||||||||||||||||
April 1, 2021, to March 31, 2022 | ||||||||||||||||||||||||||
Q1 2021 | ¥ | 141.9 | ¥ | 90.00 | March 31, 2021 | June 30, 2021 |
Persons depositing or withdrawing shares of our common stock or ADS holders must pay: | For: | |||||||
5.00 USD (or less) per 100 ADSs (or portion of 100 ADSs) | Issue of ADSs, including issues resulting from a distribution of shares of our common stock or rights or other property | |||||||
Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates | ||||||||
0.05 USD (or less) per ADS | Any cash distribution to ADS holders | |||||||
A fee equivalent to the fee that would be payable if securities distributed to ADS holders had been shares of our common stock and the shares of our common stock had been deposited for issuance of ADSs | Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to ADS holders | |||||||
0.05 USD (or less) per ADS per calendar year | Depositary services |
Registration or transfer fees | Transfer and registration of shares of our common stock on our share register to or from the name of the depositary or its agent when persons deposit or withdraw shares of our common stock | |||||||
Expenses of the depositary | Cable and facsimile transmissions (when expressly provided in the deposit agreement) | |||||||
Converting foreign currency to U.S. dollars | ||||||||
Taxes and other governmental charges the depositary or the custodian have to pay on any ADSs or shares of our common stock underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes | As necessary | |||||||
Any charges incurred by the depositary or its agents for servicing the deposited securities | As necessary |
For the fiscal year ended
March 31, |
|||||||||||||||||
2020 | 2021 | ||||||||||||||||
(billions of yen) | |||||||||||||||||
Audit fees (1)
|
¥ | 3.91 | ¥ | 3.70 | |||||||||||||
Audit‑related fees (2)
|
0.08 | 0.03 | |||||||||||||||
Tax fees (3)
|
0.00 | 0.00 | |||||||||||||||
Other fees (4)
|
0.00 | 0.00 | |||||||||||||||
Total fees
|
¥ | 3.99 | ¥ | 3.73 |
Total number of
shares purchased |
Average price
paid per share |
Total number of
shares purchased as part of publicly announced plans or programs |
Maximum
number of shares that may yet be purchased under the plans or programs |
||||||||||||||||||||||||||
April 1 to April 30, 2020 | 238 | ¥ | 3,394.82 | — | — | ||||||||||||||||||||||||
May 1 to May 31, 2020 | 520,208 | 4,093.71 | 520,200 | — | |||||||||||||||||||||||||
June 1 to June 30, 2020 | 286 | 4,027.47 | — | — | |||||||||||||||||||||||||
July 1 to July 31, 2020 | 68 | 3,742.6 | — | — | |||||||||||||||||||||||||
August 1 to August 31, 2020 | 479 | 3,911.37 | — | — | |||||||||||||||||||||||||
September 1 to September 30, 2020 | 358 | 3,919.98 | — | — | |||||||||||||||||||||||||
October 1 to October 31, 2020 | 165 | 3,589.58 | — | — | |||||||||||||||||||||||||
November 1 to November 30, 2020 | 226 | 3,489.58 | — | — | |||||||||||||||||||||||||
December 1 to December 31, 2020 | 430 | 3,826.31 | — | — | |||||||||||||||||||||||||
January 1 to January 31, 2021 | 449 | 3,633.37 | — | — | |||||||||||||||||||||||||
February 1 to February 28, 2021 | 358 | 3,715.33 | — | — | |||||||||||||||||||||||||
March 1 to March 31, 2021 | 418 | 3,880.87 | — | — | |||||||||||||||||||||||||
Total
|
523,683 | ¥ | 4,091.56 | 520,200 | — |
Exhibit
No. |
Exhibit | |||||||
Exhibit 1.1 | ||||||||
Exhibit 1.2*
|
||||||||
Exhibit 1.3 | ||||||||
Exhibit 2.1 | ||||||||
Exhibit 2.2* | ||||||||
Exhibit 4.1*+
|
||||||||
Exhibit 4.2 | ||||||||
Exhibit 4.3 | ||||||||
Exhibit 8.1 | ||||||||
Exhibit 12.1* | ||||||||
Exhibit 12.2* | ||||||||
Exhibit 13.1* | ||||||||
Exhibit 13.2* | ||||||||
Exhibit 15.1* | ||||||||
Exhibit 15.2* | ||||||||
101.INS* | Inline XBRL Instance Document—the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | |||||||
101.SCH* | Inline XBRL Taxonomy Extension Schema Document | |||||||
101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |||||||
101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |||||||
101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | |||||||
101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |||||||
104* | The cover page for the registrant’s Annual Report on Form 20-F for the year ended March 31, 2021, has been formatted in Inline XBRL |
TAKEDA PHARMACEUTICAL COMPANY LIMITED | ||||||||||||||
By:
|
/s/ Costa Saroukos | |||||||||||||
Name: Costa Saroukos | ||||||||||||||
Title: Director and Chief Financial Officer |
Page | |||||
F-13
|
|||||
F-13
|
|||||
F-14
|
|||||
F-23
|
|||||
F-26
|
|||||
F-27
|
|||||
F-27
|
|||||
F-31
|
|||||
F-32
|
|||||
F-33
|
|||||
F-36
|
|||||
F-37
|
|||||
F-39
|
|||||
F-40
|
|||||
F-42
|
|||||
F-42
|
|||||
F-42
|
|||||
F-43
|
|||||
F-43
|
|||||
F-44
|
|||||
F-46
|
|||||
F-47
|
|||||
F-52
|
|||||
F-53
|
|||||
F-54
|
|||||
F-54
|
|||||
F-56
|
|||||
F-72
|
|||||
F-76
|
|||||
F-77
|
|||||
F-78
|
|||||
F-81
|
|||||
F-84
|
JPY (millions, except per share data) | ||||||||||||||||||||
Note | 2019 | 2020 | 2021 | |||||||||||||||||
Revenue | 4 | ¥ | 2,097,224 | ¥ | 3,291,188 | ¥ | 3,197,812 | |||||||||||||
Cost of sales | (651,729) | (1,089,764) | (994,308) | |||||||||||||||||
Selling, general and administrative expenses | (717,599) | (964,737) | (875,663) | |||||||||||||||||
Research and development expenses | (368,298) | (492,381) | (455,833) | |||||||||||||||||
Amortization and impairment losses on intangible assets associated with products | 12 | (178,617) | (455,420) | (421,864) | ||||||||||||||||
Other operating income | 5 | 159,863 | 60,213 | 318,020 | ||||||||||||||||
Other operating expenses | 5 | (103,159) | (248,691) | (258,895) | ||||||||||||||||
Operating profit | 237,685 | 100,408 | 509,269 | |||||||||||||||||
Finance income | 6 | 16,843 | 27,831 | 105,521 | ||||||||||||||||
Finance expenses | 6 | (83,289) | (165,006) | (248,631) | ||||||||||||||||
Share of profit (loss) of investments accounted for using the equity method | 14 | (43,627) | (23,987) | 76 | ||||||||||||||||
Profit (loss) before tax | 127,612 | (60,754) | 366,235 | |||||||||||||||||
Income tax benefit | 7 | 7,468 | 105,044 | 9,936 | ||||||||||||||||
Net profit for the year | ¥ | 135,080 | ¥ | 44,290 | ¥ | 376,171 | ||||||||||||||
Attributable to: | ||||||||||||||||||||
Owners of the Company | 8 | ¥ | 135,192 | ¥ | 44,241 | ¥ | 376,005 | |||||||||||||
Non-controlling interests | (112) | 49 | 166 | |||||||||||||||||
Net profit for the year | ¥ | 135,080 | ¥ | 44,290 | ¥ | 376,171 | ||||||||||||||
Earnings per share (JPY) | ||||||||||||||||||||
Basic earnings per share | 8 | ¥ | 140.61 | ¥ | 28.41 | ¥ | 240.72 | |||||||||||||
Diluted earnings per share | 8 | 139.82 | 28.25 | 238.96 |
JPY (millions) | ||||||||||||||||||||
Note | 2019 | 2020 | 2021 | |||||||||||||||||
Net profit for the year | ¥ | 135,080 | ¥ | 44,290 | ¥ | 376,171 | ||||||||||||||
Other comprehensive income (loss) | ||||||||||||||||||||
Items that will not be reclassified to profit or loss: | ||||||||||||||||||||
Changes in fair value of financial assets measured at fair value through other comprehensive income | 9 | 6,000 | (3,512) | 61,866 | ||||||||||||||||
Remeasurement of defined benefit pension plans | 9 | (11,665) | (6,398) | 4,866 | ||||||||||||||||
(5,665) | (9,910) | 66,732 | ||||||||||||||||||
Items that may be reclassified subsequently to profit or loss: | ||||||||||||||||||||
Exchange differences on translation of foreign operations | 9 | 30,976 | (207,072) | 309,304 | ||||||||||||||||
Cash flow hedges | 9 | (33,793) | (25,689) | (45,345) | ||||||||||||||||
Hedging cost | 9 | (4,909) | (857) | (9,147) | ||||||||||||||||
Share of other comprehensive loss of investments accounted for using the equity method |
9, 14
|
(94) | (181) | (299) | ||||||||||||||||
(7,820) | (233,799) | 254,513 | ||||||||||||||||||
Other comprehensive income (loss) for the year, net of tax | 9 | (13,485) | (243,709) | 321,245 | ||||||||||||||||
Total comprehensive income (loss) for the year | ¥ | 121,595 | ¥ | (199,419) | ¥ | 697,416 | ||||||||||||||
Attributable to: | ||||||||||||||||||||
Owners of the Company | ¥ | 121,859 | ¥ | (199,569) | ¥ | 697,202 | ||||||||||||||
Non-controlling interests | (264) | 150 | 214 | |||||||||||||||||
Total comprehensive income (loss) for the year | ¥ | 121,595 | ¥ | (199,419) | ¥ | 697,416 |
JPY (millions) | ||||||||||||||
Note | 2020 | 2021 | ||||||||||||
Assets | ||||||||||||||
Non-current assets: | ||||||||||||||
Property, plant and equipment | 10 | ¥ | 1,386,370 | ¥ | 1,453,917 | |||||||||
Goodwill | 11 | 4,012,528 | 4,033,917 | |||||||||||
Intangible assets | 12 | 4,171,361 | 3,909,106 | |||||||||||
Investments accounted for using the equity method | 14 | 107,334 | 112,468 | |||||||||||
Other financial assets | 15 | 262,121 | 235,882 | |||||||||||
Other non-current assets | 103,846 | 100,341 | ||||||||||||
Deferred tax assets | 7 | 308,102 | 353,769 | |||||||||||
Total non-current assets | 10,351,662 | 10,199,400 | ||||||||||||
Current assets: | ||||||||||||||
Inventories | 16 | 759,599 | 753,881 | |||||||||||
Trade and other receivables | 17 | 757,005 | 783,091 | |||||||||||
Other financial assets | 15 | 15,822 | 36,598 | |||||||||||
Income taxes receivable | 27,916 | 29,623 | ||||||||||||
Other current assets | 114,196 | 122,789 | ||||||||||||
Cash and cash equivalents | 18 | 637,614 | 966,222 | |||||||||||
Assets held for sale | 19 | 157,280 | 20,689 | |||||||||||
Total current assets | 2,469,432 | 2,712,893 | ||||||||||||
Total assets | ¥ | 12,821,094 | ¥ | 12,912,293 |
JPY (millions) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity attributable to owners of the Company | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other components of equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share
capital |
Share
premium |
Treasury
shares |
Retained
earnings |
Exchange
differences on translation of foreign operations |
Changes in fair value of financial assets measured at fair value through other comprehensive income |
Net changes on
revaluation of available-for- sale financial assets |
Cash flow
hedges |
Hedging
cost |
Remeasurement of defined benefit pension plans | Total |
Other
comprehensive income related to assets held for sale |
Total | Non-controlling interests | Total equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
As of April 1, 2018 | ¥ | 77,914 | ¥ | 90,740 | ¥ | (74,373) | ¥ | 1,557,307 | ¥ | 272,597 | ¥ | — | ¥ | 73,037 | ¥ | 3,391 | ¥ | 1,606 | ¥ | — | ¥ | 350,631 | ¥ | (4,795) | ¥1,997,424 | ¥ | 19,985 | ¥ | 2,017,409 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cumulative effects of changes in accounting policies | 15,401 | 84,672 | (73,037) | (1,378) | 10,257 | 25,658 | (10) | 25,648 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restated opening balance | 77,914 | 90,740 | (74,373) | 1,572,708 | 272,597 | 84,672 | — | 2,013 | 1,606 | — | 360,888 | (4,795) | 2,023,082 | 19,975 | 2,043,057 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net profit for the year | 135,192 | — | 135,192 | (112) | 135,080 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other comprehensive income (loss) | 26,301 | 5,938 | (33,793) | (4,909) | (11,665) | (18,128) | 4,795 | (13,333) | (152) | (13,485) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Comprehensive income (loss) for the year | — | — | — | 135,192 | 26,301 | 5,938 | — | (33,793) | (4,909) | (11,665) | (18,128) | 4,795 | 121,859 | (264) | 121,595 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Transactions with owners:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of new shares
|
1,565,671 | 1,565,671 | — | 3,131,342 | 3,131,342 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisition of treasury shares
|
(1,172) | — | (1,172) | (1,172) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disposal of treasury shares
|
(0) | 3 | — | 3 | 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dividends (Note 26)
|
(142,697) | — | (142,697) | (169) | (142,866) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Changes in ownership
|
(2,337) | 230 | 230 | (2,107) | (15,536) | (17,643) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Transfers from other components of equity
|
32,565 | (44,230) | 11,665 | (32,565) | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based compensation (Note 28)
|
20,102 | — | 20,102 | 20,102 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of share-based awards (Note 28)
|
(26,281) | 18,400 | — | (7,881) | (7,881) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Basis adjustment related to acquisitions | 34,739 | 4,715 | 39,454 | 39,454 | 39,454 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total transactions with owners | 1,565,671 | 1,559,492 | 17,231 | (112,469) | 230 | (44,230) | — | 34,739 | 4,715 | 11,665 | 7,119 | — | 3,037,044 | (15,705) | 3,021,339 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
As of March 31, 2019 | ¥ | 1,643,585 | ¥ | 1,650,232 | ¥ | (57,142) | ¥ | 1,595,431 | ¥ | 299,128 | ¥ | 46,380 | ¥ | — | ¥ | 2,959 | ¥ | 1,412 | ¥ | — | ¥ | 349,879 | ¥ | — | ¥5,181,985 | ¥ | 4,006 | ¥ | 5,185,991 |
JPY (millions) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity attributable to owners of the Company | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other components of equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share
capital |
Share
premium |
Treasury
shares |
Retained
earnings |
Exchange
differences on translation of foreign operations |
Changes in fair value of financial assets measured at fair value through other comprehensive income |
Cash flow
hedges |
Hedging
cost |
Remeasurement of defined benefit pension plans | Total | Total | Non-controlling interests | Total equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
As of April 1, 2019 | ¥ | 1,643,585 | ¥ | 1,650,232 | ¥ | (57,142) | ¥ | 1,595,431 | ¥ | 299,128 | ¥ | 46,380 | ¥ | 2,959 | ¥ | 1,412 | ¥ | — | ¥ | 349,879 | ¥ | 5,181,985 | ¥ | 4,006 | ¥ | 5,185,991 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Cumulative effects of changes in accounting policies | (512) | — | (512) | (512) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restated opening balance
|
1,643,585 | 1,650,232 | (57,142) | 1,594,919 | 299,128 | 46,380 | 2,959 | 1,412 | — | 349,879 | 5,181,473 | 4,006 | 5,185,479 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net profit for the year | 44,241 | — | 44,241 | 49 | 44,290 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other comprehensive income (loss) | (207,280) | (3,586) | (25,689) | (857) | (6,398) | (243,810) | (243,810) | 101 | (243,709) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Comprehensive income (loss) for the year
|
— | — | — | 44,241 | (207,280) | (3,586) | (25,689) | (857) | (6,398) | (243,810) | (199,569) | 150 | (199,419) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Transactions with owners:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of new shares
|
24,538 | 24,538 | — | 49,076 | 49,076 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisition of treasury shares
|
(52,750) | — | (52,750) | (52,750) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disposal of treasury shares
|
(0) | 1 | — | 1 | 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dividends (Note 26)
|
(282,693) | — | (282,693) | (153) | (282,846) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Transfers from other components of equity
|
13,505 | (19,903) | 6,398 | (13,505) | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based compensation (Note 28)
|
29,122 | — | 29,122 | 29,122 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of share-based awards (Note 28)
|
(23,605) | 22,428 | — | (1,177) | (1,177) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total transactions with owners
|
24,538 | 30,055 | (30,321) | (269,188) | — | (19,903) | — | — | 6,398 | (13,505) | (258,421) | (153) | (258,574) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
As of March 31, 2020 | ¥ | 1,668,123 | ¥ | 1,680,287 | ¥ | (87,463) | ¥ | 1,369,972 | ¥ | 91,848 | ¥ | 22,891 | ¥ | (22,730) | ¥ | 555 | ¥ | — | ¥ | 92,564 | ¥ | 4,723,483 | ¥ | 4,003 | ¥ | 4,727,486 |
JPY (millions) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity attributable to owners of the Company | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other components of equity
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share
capital |
Share
premium |
Treasury
shares |
Retained
earnings |
Exchange
differences on translation of foreign operations |
Changes in fair value of financial assets measured at fair value through other comprehensive income |
Cash flow
hedges |
Hedging cost
|
Remeasurement of defined benefit pension plans |
Total
|
Total
|
Non-controlling interests
|
Total equity
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
As of April 1, 2020 | ¥ | 1,668,123 | ¥ | 1,680,287 | ¥ | (87,463) | ¥ | 1,369,972 | ¥ | 91,848 | ¥ | 22,891 | ¥ | (22,730) | ¥ | 555 | ¥ | — | ¥ | 92,564 | ¥4,723,483 | ¥ | 4,003 | ¥ | 4,727,486 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Net profit for the year
|
376,005 | — | 376,005 | 166 | 376,171 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other comprehensive income (loss)
|
308,950 | 61,873 | (45,345) | (9,147) | 4,866 | 321,197 | 321,197 | 48 | 321,245 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Comprehensive income (loss) for the year
|
— | — | — | 376,005 | 308,950 | 61,873 | (45,345) | (9,147) | 4,866 | 321,197 | 697,202 | 214 | 697,416 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Transactions with owners: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of new shares
|
22 | 22 | — | 44 | 44 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisition of treasury shares
|
(2,141) | — | (2,141) | (2,141) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disposal of treasury shares
|
(0) | 2 | — | 2 | 2 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dividends (Note 26)
|
(283,718) | — | (283,718) | (77) | (283,795) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Transfers from other components of equity
|
47,647 | (42,781) | (4,866) | (47,647) | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based compensation
(Note 28) |
37,663 | — | 37,663 | 37,663 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Exercise of share-based awards (Note 28)
|
(29,548) | 30,050 | — | 502 | 502 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total transactions with owners | 22 | 8,137 | 27,911 | (236,071) | — | (42,781) | — | — | (4,866) | (47,647) | (247,648) | (77) | (247,725) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
As of March 31, 2021 | ¥ | 1,668,145 | ¥1,688,424 | ¥ | (59,552) | ¥ | 1,509,906 | ¥ | 400,798 | ¥ | 41,983 | ¥ | (68,075) | ¥ | (8,592) | ¥ | — | ¥ | 366,114 | ¥ | 5,173,037 | ¥ | 4,140 | ¥ | 5,177,177 |
JPY (millions) | ||||||||||||||||||||
Note | 2019 | 2020 | 2021 | |||||||||||||||||
Cash flows from operating activities: | ||||||||||||||||||||
Net profit for the year | ¥ | 135,080 | ¥ | 44,290 | ¥ | 376,171 | ||||||||||||||
Depreciation and amortization | 247,691 | 583,649 | 559,671 | |||||||||||||||||
Impairment losses | 10,120 | 101,882 | 25,452 | |||||||||||||||||
Equity-settled share-based compensation | 20,084 | 29,122 | 37,663 | |||||||||||||||||
Change in estimate of liabilities related to SHP647 | 5 | — | — | (60,179) | ||||||||||||||||
Gain on sales and disposal of property, plant and equipment | (45,220) | (990) | (2,109) | |||||||||||||||||
Gain on divestment of business and subsidiaries | (82,975) | (16,755) | (229,993) | |||||||||||||||||
Loss (gain) on liquidation of foreign operations | (2,669) | 399 | — | |||||||||||||||||
Change in fair value of financial assets and liabilities associated with contingent consideration arrangements, net | (5,966) | (18,387) | 59,277 | |||||||||||||||||
Finance (income) and expenses, net | 66,446 | 137,175 | 143,110 | |||||||||||||||||
Share of loss (profit) of investments accounted for using the equity method | 43,627 | 23,987 | (76) | |||||||||||||||||
Income tax benefit | (7,468) | (105,044) | (9,936) | |||||||||||||||||
Changes in assets and liabilities: | ||||||||||||||||||||
Increase in trade and other receivables | (13,382) | (34,826) | (9,316) | |||||||||||||||||
Decrease in inventories | 50,717 | 137,492 | 25,978 | |||||||||||||||||
Increase (decrease) in trade and other payables | (16,413) | (29,932) | 36,620 | |||||||||||||||||
Increase in provisions | 47,063 | 21,938 | 49,099 | |||||||||||||||||
Increase (decrease) in other financial liabilities | (4,008) | 7,158 | 173,400 | |||||||||||||||||
Other, net | (69,339) | 15,362 | 37,786 | |||||||||||||||||
Cash generated from operations | 373,388 | 896,520 | 1,212,618 | |||||||||||||||||
Income taxes paid | (51,536) | (234,612) | (235,801) | |||||||||||||||||
Tax refunds and interest on tax refunds received | 6,627 | 7,844 | 34,114 | |||||||||||||||||
Net cash from operating activities | 328,479 | 669,752 | 1,010,931 | |||||||||||||||||
Cash flows from investing activities: | ||||||||||||||||||||
Interest received | 6,305 | 11,487 | 1,105 | |||||||||||||||||
Dividends received | 2,739 | 1,382 | 387 | |||||||||||||||||
Acquisition of property, plant and equipment | (77,677) | (127,082) | (111,206) | |||||||||||||||||
Proceeds from sales of property, plant and equipment | 50,717 | 12,578 | 46,453 | |||||||||||||||||
Acquisition of intangible assets | (56,437) | (90,628) | (125,262) | |||||||||||||||||
Acquisition of investments | (17,099) | (7,551) | (12,596) | |||||||||||||||||
Proceeds from sales and redemption of investments | 65,035 | 49,402 | 74,604 | |||||||||||||||||
Acquisition of businesses, net of cash and cash equivalents acquired | (2,958,686) | (4,890) | — | |||||||||||||||||
Proceeds from sales of business, net of cash and cash equivalents divested | 85,131 | 461,546 | 530,388 | |||||||||||||||||
Proceeds from withdrawal of restricted deposits | 71,844 | — | — | |||||||||||||||||
Other, net | (7,570) | (14,125) | (10,343) | |||||||||||||||||
Net cash from (used in) investing activities | (2,835,698) | 292,119 | 393,530 | |||||||||||||||||
Cash flows from financing activities: | ||||||||||||||||||||
Net increase (decrease) in short-term loans and commercial papers | 27 | 367,319 | (351,223) | (149,043) | ||||||||||||||||
Proceeds from issuance of bonds and long-term loans | 27 | 2,795,926 | 496,190 | 1,179,515 | ||||||||||||||||
Repayments of bonds and long-term loans | 27 | — | (701,057) | (1,651,706) | ||||||||||||||||
Payments for settlement of forward rate agreement related to bonds | — | — | (34,830) | |||||||||||||||||
Acquisition of treasury shares | (1,172) | (3,737) | (2,141) | |||||||||||||||||
Interest paid | (34,914) | (127,211) | (107,350) | |||||||||||||||||
Dividends paid | (142,952) | (282,582) | (283,357) | |||||||||||||||||
Acquisition of non-controlling interests | (2,392) | (1,700) | — | |||||||||||||||||
Repayments of lease liabilities (2019: Repayments of obligations under finance lease) | 27 | (1,741) | (30,000) | (39,270) | ||||||||||||||||
Facility fees paid for loan agreements | (19,507) | — | — | |||||||||||||||||
Other, net | (14,330) | (3,893) | (172) | |||||||||||||||||
Net cash from (used in) financing activities | 2,946,237 | (1,005,213) | (1,088,354) | |||||||||||||||||
Net increase (decrease) in cash and cash equivalents | 439,018 | (43,342) | 316,107 | |||||||||||||||||
Cash and cash equivalents at the beginning of the year | ||||||||||||||||||||
(Consolidated statements of financial position) | 18 | 294,522 | 702,093 | 637,614 | ||||||||||||||||
Cash and cash equivalents reclassified back from assets held for sale | 451 | 629 | — | |||||||||||||||||
Cash and cash equivalents at the beginning of the year | 294,973 | 702,722 | 637,614 | |||||||||||||||||
Effects of exchange rate changes on cash and cash equivalents | (31,269) | (21,766) | 12,501 | |||||||||||||||||
Cash and cash equivalents at the end of the year | 702,722 | 637,614 | 966,222 | |||||||||||||||||
Cash and cash equivalents reclassified to assets held for sale | (629) | — | — | |||||||||||||||||
Cash and cash equivalents at the end of the year | ||||||||||||||||||||
(Consolidated statements of financial position) | 18 | 702,093 | 637,614 | 966,222 |
2019 | 2020 | 2021 | |||||||||||||||
Gastroenterology: | |||||||||||||||||
ENTYVIO | ¥ | 269,199 | ¥ | 347,196 | ¥ | 429,281 | |||||||||||
TAKECAB-F (1)
|
58,241 | 72,713 | 84,822 | ||||||||||||||
GATTEX/REVESTIVE | 12,753 | 61,812 | 64,564 | ||||||||||||||
DEXILANT | 69,197 | 62,797 | 55,572 | ||||||||||||||
PANTOLOC/CONTROLOC (2)
|
61,629 | 49,463 | 43,120 | ||||||||||||||
ALOFISEL | 45 | 373 | 784 | ||||||||||||||
Others | 68,254 | 103,542 | 99,657 | ||||||||||||||
Total Gastroenterology | 539,318 | 697,896 | 777,800 | ||||||||||||||
Rare Diseases: | |||||||||||||||||
Rare Metabolic: | |||||||||||||||||
ELAPRASE | 15,083 | 67,924 | 68,786 | ||||||||||||||
REPLAGAL | 11,437 | 51,253 | 51,764 | ||||||||||||||
VPRIV | 8,688 | 38,013 | 38,518 | ||||||||||||||
NATPARA/NATPAR | 7,094 | 13,635 | 3,552 | ||||||||||||||
Total Rare Metabolic | 42,302 | 170,825 | 162,620 | ||||||||||||||
Rare Hematology: | |||||||||||||||||
ADVATE | 32,099 | 157,856 | 128,535 | ||||||||||||||
ADYNOVATE/ADYNOVI | 10,740 | 58,672 | 58,070 | ||||||||||||||
FEIBA | 9,634 | 51,508 | 44,495 | ||||||||||||||
RECOMBINATE | 2,769 | 17,089 | 13,389 | ||||||||||||||
Others | 11,462 | 49,115 | 45,310 | ||||||||||||||
Total Rare Hematology | 66,704 | 334,240 | 289,799 | ||||||||||||||
Hereditary Angioedema: | |||||||||||||||||
TAKHZYRO | 9,729 | 68,271 | 86,718 | ||||||||||||||
FIRAZYR | 6,416 | 32,662 | 26,824 | ||||||||||||||
Others | 4,270 | 28,890 | 25,785 | ||||||||||||||
Total HAE (Hereditary Angioedema) | 20,415 | 129,823 | 139,327 | ||||||||||||||
Total Rare Diseases | 129,421 | 634,888 | 591,746 |
PDT Immunology: | |||||||||||||||||
immunoglobulin | 73,462 | 298,697 | 334,874 | ||||||||||||||
albumin | 12,299 | 67,215 | 57,580 | ||||||||||||||
Others | 7,718 | 28,253 | 27,935 | ||||||||||||||
Total PDT Immunology | 93,479 | 394,165 | 420,389 | ||||||||||||||
Oncology: | |||||||||||||||||
VELCADE | 127,869 | 118,321 | 101,112 | ||||||||||||||
LEUPLIN/ENANTONE | 110,074 | 109,048 | 95,365 | ||||||||||||||
NINLARO | 62,171 | 77,555 | 87,396 | ||||||||||||||
ADCETRIS | 42,903 | 52,672 | 59,432 | ||||||||||||||
ICLUSIG | 28,705 | 31,815 | 34,193 | ||||||||||||||
ALUNBRIG | 5,199 | 7,237 | 8,806 | ||||||||||||||
Others | 22,519 | 24,308 | 30,208 | ||||||||||||||
Total Oncology | 399,440 | 420,956 | 416,512 | ||||||||||||||
Neuroscience: | |||||||||||||||||
VYVANSE/ELVANSE | 49,354 | 274,077 | 271,531 | ||||||||||||||
TRINTELLIX | 57,550 | 70,666 | 68,869 | ||||||||||||||
Others | 47,766 | 93,777 | 76,897 | ||||||||||||||
Total Neuroscience | 154,670 | 438,520 | 417,297 | ||||||||||||||
Other: | |||||||||||||||||
AZILVA-F (1)
|
70,762 | 76,749 | 82,205 | ||||||||||||||
NESINA/VIPIDIA-F (1)
|
54,789 | 57,958 | 57,670 | ||||||||||||||
LOTRIGA | 30,856 | 31,752 | 31,765 | ||||||||||||||
Others (3)
|
624,489 | 538,304 | 402,428 | ||||||||||||||
Total Other | 780,896 | 704,763 | 574,068 | ||||||||||||||
Total | ¥ | 2,097,224 | ¥ | 3,291,188 | ¥ | 3,197,812 |
JPY (millions)
For the Year Ended March 31 |
|||||||||||||||||||||||||||||||||||||||||||||||
Japan
|
United States
|
Europe and Canada
|
Russia/ CIS
|
Latin America
|
Asia
|
Other
|
Total
|
||||||||||||||||||||||||||||||||||||||||
2019 | ¥ | 571,016 | ¥ | 828,985 | ¥ | 405,641 | ¥ | 59,741 | ¥ | 88,115 | ¥ | 105,411 | ¥ | 38,315 | ¥ | 2,097,224 | |||||||||||||||||||||||||||||||
2020 | 592,786 | 1,595,922 | 645,528 | 76,835 | 143,456 | 165,401 | 71,260 | 3,291,188 | |||||||||||||||||||||||||||||||||||||||
2021 | 559,748 | 1,567,931 | 666,177 | 57,560 | 121,638 | 156,240 | 68,518 | 3,197,812 |
JPY (millions)
As of March 31
|
|||||||||||||||||||||||||||||
Japan
|
United States
|
Switzerland
|
Other
|
Total
|
|||||||||||||||||||||||||
2020 | ¥ | 385,709 | ¥ | 6,533,733 | ¥ | 1,484,238 | ¥ | 1,240,046 | ¥ | 9,643,726 | |||||||||||||||||||
2021 | 413,402 | 6,345,039 | 1,494,239 | 1,210,197 | 9,462,877 |
JPY (millions)
For the Year Ended March 31 |
|||||||||||||||||
2019 | 2020 | 2021 | |||||||||||||||
Current tax expenses
|
¥ | 61,606 | ¥ | 238,856 | ¥ | 131,952 | |||||||||||
Deferred tax benefits
|
(69,074) | (343,900) | (141,888) | ||||||||||||||
Total
|
¥ | (7,468) | ¥ | (105,044) | ¥ | (9,936) |
JPY (millions)
As of March 31 |
|||||||||||
2020 | 2021 | ||||||||||
Deferred tax assets
|
¥ | 308,102 | ¥ | 353,769 | |||||||
Deferred tax liabilities
|
(710,147) | (542,852) | |||||||||
Net deferred tax liabilities
|
¥ | (402,045) | ¥ | (189,083) |
JPY (millions) | |||||||||||||||||||||||||||||
As of April 1, 2020 | Recognized in profit or (loss) | Recognized in other comprehensive income |
Other(1)
|
As of March 31, 2021 | |||||||||||||||||||||||||
Research and development expenses | ¥ | 33,175 | ¥ | 1,837 | ¥ | — | ¥ | 449 | ¥ | 35,461 | |||||||||||||||||||
Inventories | 42,557 | 35,228 | — | 12,944 | 90,729 | ||||||||||||||||||||||||
Property, plant and equipment | (82,527) | 5,612 | — | (3,429) | (80,344) | ||||||||||||||||||||||||
Intangible assets | (699,850) | 113,219 | — | 24,681 | (561,950) | ||||||||||||||||||||||||
Financial assets measured at FVTOCI | (19,417) | 506 | (17,498) | 12,643 | (23,766) | ||||||||||||||||||||||||
Accrued expenses and provisions | 135,920 | 8,822 | — | (5,503) | 139,239 | ||||||||||||||||||||||||
Defined benefit plans | 23,084 | (6,322) | 2,719 | (211) | 19,270 | ||||||||||||||||||||||||
Deferred income | 14,713 | 6,191 | — | 66 | 20,970 | ||||||||||||||||||||||||
Unused tax losses | 124,891 | 2,690 | 25,066 | (1,696) | 150,951 | ||||||||||||||||||||||||
Tax credits | 82,124 | (18,504) | — | (1,231) | 62,389 | ||||||||||||||||||||||||
Investments in subsidiaries and associates | (62,859) | (6,027) | — | (265) | (69,151) | ||||||||||||||||||||||||
Other | 6,144 | (1,364) | 24,004 | (1,665) | 27,119 | ||||||||||||||||||||||||
Total | ¥ | (402,045) | ¥ | 141,888 | ¥ | 34,291 | ¥ | 36,783 | ¥ | (189,083) |
JPY (millions)
As of March 31 |
|||||||||||
2020 | 2021 | ||||||||||
Unused tax losses | ¥ | 1,580,235 | ¥ | 1,533,050 | |||||||
Deductible temporary differences | 333,336 | 241,203 | |||||||||
Unused tax credits | 9,278 | 9,660 |
JPY (millions)
As of March 31 |
|||||||||||
Unused tax credits | 2020 | 2021 | |||||||||
Less than 5 years | ¥ | 2,606 | ¥ | 1,370 | |||||||
5 years or more | 6,394 | 8,290 | |||||||||
Indefinite | 278 | — | |||||||||
Total | ¥ | 9,278 | ¥ | 9,660 |
For the Year Ended March 31 | |||||||||||||||||
2019 | 2020 | 2021 | |||||||||||||||
Net profit for the year attributable to owners of the Company:
|
|||||||||||||||||
Net profit for the year attributable to owners of the Company JPY (millions)
|
¥ | 135,192 | ¥ | 44,241 | ¥ | 376,005 | |||||||||||
Net profit used for calculation of earnings per share JPY (millions)
|
135,192 | 44,241 | 376,005 | ||||||||||||||
Weighted-average number of ordinary shares outstanding during the year (thousands of shares) [basic]
|
961,477 | 1,557,204 | 1,562,006 | ||||||||||||||
Dilutive effect (thousands of shares)
|
5,420 | 9,000 | 11,531 | ||||||||||||||
Weighted-average number of ordinary shares outstanding during the year (thousands of shares) [diluted]
|
966,897 | 1,566,204 | 1,573,537 | ||||||||||||||
Earnings per share
|
|||||||||||||||||
Basic (JPY)
|
140.61 | 28.41 | 240.72 | ||||||||||||||
Diluted (JPY)
|
139.82 | 28.25 | 238.96 |
JPY (millions) | |||||||||||||||||||||||||||||||||||
Acquisition cost |
Buildings and structures
|
Machinery and vehicles
|
Tools, furniture, and fixtures
|
Land
|
Construction in progress
|
Total
|
|||||||||||||||||||||||||||||
As of March 31, 2019 | ¥ | 957,045 | ¥ | 648,974 | ¥ | 122,136 | ¥ | 100,808 | ¥ | 142,559 | ¥ | 1,971,522 | |||||||||||||||||||||||
Adoption of IFRS 16 | 187,986 | 11,222 | 48 | — | — | 199,256 | |||||||||||||||||||||||||||||
As of April 1, 2019 | ¥ | 1,145,031 | ¥ | 660,196 | ¥ | 122,184 | ¥ | 100,808 | ¥ | 142,559 | ¥ | 2,170,778 | |||||||||||||||||||||||
Additions | 23,745 | 11,548 | 10,269 | 2,290 | 93,097 | 140,949 | |||||||||||||||||||||||||||||
Transfers | (35,993) | 23,232 | 8,153 | 11 | (57,826) | (62,423) | |||||||||||||||||||||||||||||
Disposals and other decreases | (14,354) | (10,391) | (9,374) | — | (195) | (34,314) | |||||||||||||||||||||||||||||
Reclassification to assets held for sale (Note 19) | (26,786) | (7,042) | (296) | (3,465) | (45,286) | (82,875) | |||||||||||||||||||||||||||||
Foreign currency translation differences | (18,979) | (16,990) | (4,012) | (3,015) | (4,726) | (47,722) | |||||||||||||||||||||||||||||
Other | (661) | (861) | 1,930 | — | (677) | (269) | |||||||||||||||||||||||||||||
As of March 31, 2020 | ¥ | 1,072,003 | ¥ | 659,692 | ¥ | 128,854 | ¥ | 96,629 | ¥ | 126,946 | ¥ | 2,084,124 | |||||||||||||||||||||||
Additions | 109,034 | 22,318 | 8,376 | — | 74,010 | 213,738 | |||||||||||||||||||||||||||||
Transfers | 27,164 | 32,125 | 5,523 | (145) | (64,667) | — | |||||||||||||||||||||||||||||
Disposals and other decreases | (91,232) | (24,306) | (14,172) | (2,917) | (926) | (133,553) | |||||||||||||||||||||||||||||
Reclassification to assets held for sale (Note 19) | (13,413) | (21,030) | (3,071) | (808) | (327) | (38,649) | |||||||||||||||||||||||||||||
Foreign currency translation differences | 29,853 | 17,398 | 8,444 | 2,475 | 8,099 | 66,269 | |||||||||||||||||||||||||||||
Other | (3) | (62) | (125) | 1 | (5) | (194) | |||||||||||||||||||||||||||||
As of March 31, 2021 | ¥ | 1,133,406 | ¥ | 686,135 | ¥ | 133,829 | ¥ | 95,235 | ¥ | 143,130 | ¥ | 2,191,735 |
Accumulated depreciation and accumulated impairment losses | |||||||||||||||||||||||||||||||||||
As of April 1, 2019 | ¥ | (250,148) | ¥ | (311,317) | ¥ | (74,962) | ¥ | (374) | ¥ | (2,790) | ¥ | (639,591) | |||||||||||||||||||||||
Depreciation expenses | (60,570) | (58,860) | (19,324) | — | — | (138,754) | |||||||||||||||||||||||||||||
Impairment losses | (18,057) | (710) | (647) | (601) | — | (20,015) | |||||||||||||||||||||||||||||
Transfers | 37,101 | 3,931 | 882 | — | — | 41,914 | |||||||||||||||||||||||||||||
Disposals and other decreases | 3,842 | 7,816 | 8,835 | — | — | 20,493 | |||||||||||||||||||||||||||||
Reclassification to assets held for sale (Note 19) | 17,600 | 5,158 | 252 | — | — | 23,010 | |||||||||||||||||||||||||||||
Foreign currency translation differences | 7,427 | 6,856 | 2,449 | 15 | 8 | 16,755 | |||||||||||||||||||||||||||||
Other | (439) | 1,491 | (2,618) | — | — | (1,566) | |||||||||||||||||||||||||||||
As of March 31, 2020 | ¥ | (263,244) | ¥ | (345,635) | ¥ | (85,133) | ¥ | (960) | ¥ | (2,782) | ¥ | (697,754) | |||||||||||||||||||||||
Depreciation expenses | (53,061) | (55,794) | (15,549) | — | — | (124,404) | |||||||||||||||||||||||||||||
Impairment losses | (161) | (105) | (67) | — | (103) | (436) | |||||||||||||||||||||||||||||
Transfers | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Disposals and other decreases | 53,017 | 18,978 | 13,508 | 601 | 15 | 86,119 | |||||||||||||||||||||||||||||
Reclassification to assets held for sale (Note 19) | 6,319 | 14,748 | 2,171 | — | — | 23,238 | |||||||||||||||||||||||||||||
Foreign currency translation differences | (9,037) | (6,716) | (7,807) | (72) | (100) | (23,732) | |||||||||||||||||||||||||||||
Other | (538) | (321) | 11 | — | (1) | (849) | |||||||||||||||||||||||||||||
As of March 31, 2021 | ¥ | (266,705) | ¥ | (374,845) | ¥ | (92,866) | ¥ | (431) | ¥ | (2,971) | ¥ | (737,818) |
JPY (millions) | |||||||||||||||||||||||
Acquisition cost of ROU Assets | Buildings and structures | Machinery and vehicles | Tools, furniture, and fixtures | Total | |||||||||||||||||||
As of April 1, 2019 | ¥ | 396,824 | ¥ | 15,981 | ¥ | 864 | ¥ | 413,669 | |||||||||||||||
Additions | 16,077 | 2,211 | 93 | 18,381 | |||||||||||||||||||
Disposals and other decreases | (11,666) | (3,329) | (239) | (15,234) | |||||||||||||||||||
Reclassification to assets held for sale (Note 19) | (1,545) | (47) | — | (1,592) | |||||||||||||||||||
Foreign currency translation differences | (1,604) | (503) | (2) | (2,109) | |||||||||||||||||||
Other | 355 | (345) | 2 | 12 | |||||||||||||||||||
As of March 31, 2020 | ¥ | 398,441 | ¥ | 13,968 | ¥ | 718 | ¥ | 413,127 | |||||||||||||||
Additions | 87,721 | 7,880 | 54 | 95,655 | |||||||||||||||||||
Disposals and other decreases | (29,473) | (7,048) | (313) | (36,834) | |||||||||||||||||||
Reclassification to assets held for sale (Note 19) | (3,190) | (175) | — | (3,365) | |||||||||||||||||||
Foreign currency translation differences | 9,750 | 501 | 14 | 10,265 | |||||||||||||||||||
Other | (452) | (86) | (1) | (539) | |||||||||||||||||||
As of March 31, 2021 | ¥ | 462,797 | ¥ | 15,040 | ¥ | 472 | ¥ | 478,309 |
Accumulated amortization and
accumulated impairment losses |
|||||||||||||||||||||||
As of April 1, 2019 | ¥ | (62,943) | ¥ | (1,220,429) | ¥ | (10,979) | ¥ | (1,294,351) | |||||||||||||||
Amortization | (32,771) | (412,074) | (29) | (444,874) | |||||||||||||||||||
Impairment losses | (4,731) | (43,346) | — | (48,077) | |||||||||||||||||||
Disposals and other decreases | 19,784 | 3,029 | 10,573 | 33,386 | |||||||||||||||||||
Reclassification to assets held for sale (Note 19) | — | 96,608 | — | 96,608 | |||||||||||||||||||
Foreign currency translation differences | 2,101 | 46,629 | — | 48,730 | |||||||||||||||||||
As of March 31, 2020 | ¥ | (78,560) | ¥ | (1,529,583) | ¥ | (435) | ¥ | (1,608,578) | |||||||||||||||
Amortization | (28,346) | (405,268) | — | (433,614) | |||||||||||||||||||
Impairment losses | (39) | (16,596) | — | (16,635) | |||||||||||||||||||
Disposals and other decreases | 8,354 | — | — | 8,354 | |||||||||||||||||||
Reclassification to assets held for sale (Note 19) | 531 | 39,260 | — | 39,791 | |||||||||||||||||||
Deconsolidation | (20) | — | — | (20) | |||||||||||||||||||
Foreign currency translation differences | (5,314) | 8,636 | — | 3,322 | |||||||||||||||||||
As of March 31, 2021 | ¥ | (103,394) | ¥ | (1,903,551) | ¥ | (435) | ¥ | (2,007,380) | |||||||||||||||
Carrying amount | |||||||||||||||||||||||
As of April 1, 2019 | ¥ | 97,294 | ¥ | 4,642,521 | ¥ | 11,354 | ¥ | 4,751,169 | |||||||||||||||
As of March 31, 2020 | 86,360 | 4,073,670 | 11,331 | 4,171,361 | |||||||||||||||||||
As of March 31, 2021 | 95,471 | 3,802,484 | 11,151 | 3,909,106 |
JPY (millions)
Carrying amount
|
Remaining amortization period | |||||||||||||||||||
As of March 31 | As of March 31 | |||||||||||||||||||
2020 | 2021 | 2021 | ||||||||||||||||||
immunoglobulin | Marketed products | ¥ | 788,628 | ¥ | 753,203 | 14 years | ||||||||||||||
TAKHZYRO | Marketed products | 567,589 | 536,445 | 13 years | ||||||||||||||||
VYVANSE | Marketed products | 517,695 | 441,577 | 5 years | ||||||||||||||||
ADVATE & ADYNOVATE | Marketed products | 313,509 | 293,697 | 9 years | ||||||||||||||||
ALUNBRIG | In-process R&D | 160,580 | — | — | ||||||||||||||||
Marketed products | 76,688 | 220,969 | 10 years |
Discount rate
(Post-tax) |
|||||||||||
March 31, 2019 | 11.0% | ||||||||||
March 31, 2020 |
7.0% - 8.0%
|
||||||||||
March 31, 2021 | 7.0% |
JPY (millions)
|
|||||||||||||||||
2019 | 2020 | 2021 | |||||||||||||||
Initial up-front and milestone payments | ¥ | 29,857 | ¥ | 77,016 | ¥ | 84,034 | |||||||||||
Acquisition of shares of collaboration and in-licensing partners
|
5,994 | 1,317 | 1,504 |
JPY (millions)
As of March 31 |
|||||||||||
2020 | 2021 | ||||||||||
Carrying amount of investments accounted for using the equity method | ¥ | 33,367 | ¥ | 45,812 |
JPY (millions)
As of March 31 |
|||||||||||
2020 | 2021 | ||||||||||
Finished products and merchandise | ¥ | 205,979 | ¥ | 216,403 | |||||||
Work-in-process | 395,842 | 387,917 | |||||||||
Raw materials and supplies | 157,778 | 149,561 | |||||||||
Total | ¥ | 759,599 | ¥ | 753,881 |
JPY (millions)
As of March 31 |
|||||||||||
2020 | 2021 | ||||||||||
Cash and deposits | ¥ | 188,640 | ¥ | 335,027 | |||||||
Short-term investments | 448,974 | 631,195 | |||||||||
Total | ¥ | 637,614 | ¥ | 966,222 |
JPY (millions)
For the Year Ended March 31 |
|||||||||||||||||
2019 | 2020 | 2021 | |||||||||||||||
Japan | ¥ | 4,621 | ¥ | 4,769 | ¥ | (2,696) | |||||||||||
Foreign | 6,786 | 11,493 | 10,655 | ||||||||||||||
Defined benefit costs | ¥ | 11,407 | ¥ | 16,262 | ¥ | 7,959 |
Discount rate | Future salary increases | ||||||||||
2020 | |||||||||||
Japan | 0.6 | % | 2.6 | % | |||||||
Foreign | 1.7 | % | 2.9 | % | |||||||
2021 | |||||||||||
Japan | 0.7 | % | 2.5 | % | |||||||
Foreign | 1.4 | % | 2.7 | % |
JPY (millions)
For the Year Ended March 31 |
|||||||||||
2020 | 2021 | ||||||||||
Balance at beginning of the year | ¥ | — | ¥ | — | |||||||
Remeasurement
Changes in effect of asset ceiling
|
— | 25,757 | |||||||||
Balance at end of the year | ¥ | — | ¥ | 25,757 |
JPY (millions)
For the Year Ended March 31 |
|||||||||||||||||
2019 | 2020 | 2021 | |||||||||||||||
Salary | ¥ | 272,930 | ¥ | 417,860 | ¥ | 418,087 | |||||||||||
Bonuses | 89,439 | 135,938 | 105,772 | ||||||||||||||
Other | 93,711 | 157,722 | 163,443 |
JPY (millions)
As of March 31 |
|||||||||||
2020 | 2021 | ||||||||||
Trade payables | ¥ | 211,627 | ¥ | 232,105 | |||||||
Other payables | 107,189 | 111,733 | |||||||||
Total | ¥ | 318,816 | ¥ | 343,838 |
Thousands of Shares
For the Year Ended March 31 |
|||||||||||
2020 | 2021 | ||||||||||
Authorized shares as of the beginning of the year
|
3,500,000 | 3,500,000 | |||||||||
Shares issued: | |||||||||||
At the beginning of the year
|
1,565,006 | 1,576,374 | |||||||||
Exercise of stock options
|
18 | 14 | |||||||||
Issuance of shares
|
11,350 | — | |||||||||
As of the end of the year
|
1,576,374 | 1,576,388 |
Dividends declared and paid |
JPY (millions)
Total dividends |
Dividends per share JPY | Record date | Effective date | ||||||||||||||||||||||
April 1, 2018, to March 31, 2019
|
||||||||||||||||||||||||||
Q1 2018
|
¥ | 71,507 | ¥ | 90.00 | March 31, 2018 | June 29, 2018 | ||||||||||||||||||||
Q3 2018
|
71,509 | 90.00 | September 30, 2018 | December 3, 2018 | ||||||||||||||||||||||
April 1, 2019, to March 31, 2020
|
||||||||||||||||||||||||||
Q1 2019
|
140,836 | 90.00 | March 31, 2019 | June 28, 2019 | ||||||||||||||||||||||
Q3 2019
|
141,857 | 90.00 | September 30, 2019 | December 2, 2019 | ||||||||||||||||||||||
April 1, 2020, to March 31, 2021
|
||||||||||||||||||||||||||
Q1 2020
|
141,858 | 90.00 | March 31, 2020 | June 25, 2020 | ||||||||||||||||||||||
Q3 2020
|
141,860 | 90.00 | September 30, 2020 | December 1, 2020 |
Dividends declared |
JPY (millions)
Total dividends |
Dividends per share JPY | Record date | Effective date | ||||||||||||||||||||||
April 1, 2021, to March 31, 2022
|
||||||||||||||||||||||||||
Q1 2021 | ¥ | 141,859 | ¥ | 90.00 | March 31, 2021 | June 30, 2021 |
JPY (millions)
As of March 31, 2021 |
|||||||||||||||||||||||||||||||||||
Financial assets measured at amortized
cost |
Measured at fair value through other comprehensive income | Measured at fair value through profit or loss | Derivative hedging instruments | Other financial liabilities | Total | ||||||||||||||||||||||||||||||
Financial assets measured at fair value | |||||||||||||||||||||||||||||||||||
Other financial assets - | |||||||||||||||||||||||||||||||||||
Equity instruments | ¥ | — | ¥ | 145,070 | ¥ | — | ¥ | — | ¥ | — | ¥ | 145,070 | |||||||||||||||||||||||
Derivative financial instruments | — | — | 62,594 | 1,506 | — | 64,100 | |||||||||||||||||||||||||||||
Investments in convertible notes | — | — | 12,176 | — | — | 12,176 | |||||||||||||||||||||||||||||
Investments in debt instruments | — | — | 800 | — | — | 800 | |||||||||||||||||||||||||||||
Financial assets associated with contingent consideration arrangements | — | — | 25,446 | — | — | 25,446 | |||||||||||||||||||||||||||||
Total
|
¥ | — | ¥ | 145,070 | ¥ | 101,016 | ¥ | 1,506 | ¥ | — | ¥ | 247,592 | |||||||||||||||||||||||
Financial assets not measured at fair value | |||||||||||||||||||||||||||||||||||
Other financial assets - | |||||||||||||||||||||||||||||||||||
Other | ¥ | 24,888 | ¥ | — | ¥ | — | ¥ | — | ¥ | — | ¥ | 24,888 | |||||||||||||||||||||||
Trade and other receivables | 783,091 | — | — | — | — | 783,091 | |||||||||||||||||||||||||||||
Cash and cash equivalents | 966,222 | — | — | — | — | 966,222 | |||||||||||||||||||||||||||||
Total | ¥ | 1,774,201 | ¥ | — | ¥ | — | ¥ | — | ¥ | — | ¥ | 1,774,201 | |||||||||||||||||||||||
Financial liabilities measured at fair value | |||||||||||||||||||||||||||||||||||
Other financial liabilities - | |||||||||||||||||||||||||||||||||||
Derivative financial instruments | ¥ | — | ¥ | — | ¥ | 12,116 | ¥ | 84,975 | ¥ | — | ¥ | 97,091 | |||||||||||||||||||||||
Financial liabilities associated with contingent consideration arrangements | — | — | 27,770 | — | — | 27,770 | |||||||||||||||||||||||||||||
Other | — | — | 2,693 | — | — | 2,693 | |||||||||||||||||||||||||||||
Total
|
¥ | — | ¥ | — | ¥ | 42,579 | ¥ | 84,975 | ¥ | — | ¥ | 127,554 | |||||||||||||||||||||||
Financial liabilities not measured at fair value | |||||||||||||||||||||||||||||||||||
Other financial liabilities -
|
|||||||||||||||||||||||||||||||||||
Lease liabilities | ¥ | — | ¥ | — | ¥ | — | ¥ | — | ¥ | 436,412 | ¥ | 436,412 | |||||||||||||||||||||||
Other | — | — | — | — | 201,764 | 201,764 | |||||||||||||||||||||||||||||
Trade and other payables | — | — | — | — | 343,838 | 343,838 | |||||||||||||||||||||||||||||
Bonds and loans | — | — | — | — | 4,635,371 | 4,635,371 | |||||||||||||||||||||||||||||
Total | ¥ | — | ¥ | — | ¥ | — | ¥ | — | ¥ | 5,617,385 | ¥ | 5,617,385 |
JPY (millions)
As of March 31, 2021
|
|||||||||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | ||||||||||||||||||||
Assets: | |||||||||||||||||||||||
Financial assets measured at fair value through profit or loss | |||||||||||||||||||||||
Derivatives
|
¥ | — | ¥ | 62,594 | ¥ | — | ¥ | 62,594 | |||||||||||||||
Investment in convertible notes
|
— | — | 12,176 | 12,176 | |||||||||||||||||||
Investment in debt instruments | — | — | 800 | 800 | |||||||||||||||||||
Financial assets associated with contingent consideration arrangements
|
— | — | 25,446 | 25,446 | |||||||||||||||||||
Derivatives for which hedge accounting is applied | — | 1,506 | — | 1,506 | |||||||||||||||||||
Financial assets measured at fair value through OCI | |||||||||||||||||||||||
Equity instruments
|
92,602 | — | 52,468 | 145,070 | |||||||||||||||||||
Total | ¥ | 92,602 | ¥ | 64,100 | ¥ | 90,890 | ¥ | 247,592 | |||||||||||||||
Liabilities: | |||||||||||||||||||||||
Financial liabilities measured at fair value through profit or loss | |||||||||||||||||||||||
Derivatives
|
¥ | — | ¥ | 12,116 | ¥ | — | ¥ | 12,116 | |||||||||||||||
Financial liabilities associated with contingent consideration arrangements
|
— | — | 27,770 | 27,770 | |||||||||||||||||||
Other
|
— | — | 2,693 | 2,693 | |||||||||||||||||||
Derivative for which hedge accounting is applied
|
— | 84,975 | — | 84,975 | |||||||||||||||||||
Total | ¥ | — | ¥ | 97,091 | ¥ | 30,463 | ¥ | 127,554 |
JPY (millions)
As of March 31
|
|||||||||||||||||
Contract amount | Contract amount to be settled in more than one year | Fair value | |||||||||||||||
2020 | ¥ | 640,205 | ¥ | 184,450 | ¥ | (38,796) | |||||||||||
2021 | 164,443 | 164,443 | (3,271) |
JPY (millions)
As of March 31, 2020
|
|||||||||||
Balance in cash flow hedges and net investment hedges | Balance in hedge cost reserve | ||||||||||
Cash flow hedges | |||||||||||
Interest risk | |||||||||||
Interest rate swaps | ¥ | (5,070) | ¥ | — | |||||||
Forward interest rate | (21,488) | — | |||||||||
Currency and interest risk | |||||||||||
Currency and interest rate swaps | 266 | 555 | |||||||||
Currency risk | |||||||||||
Hedge related to acquisition | 3,560 | — | |||||||||
Net investment hedges | |||||||||||
Foreign currency denominated bonds and loans | 71,795 | — |
JPY (millions) except for percentage
As of March 31, 2020 |
|||||||||||||||||||||||||||||||||||||||||
Amount past due | |||||||||||||||||||||||||||||||||||||||||
Current |
Within 30
days |
Over 30 days but within 60 days | Over 60 days but within 90 days | Over 90 days but within one year |
Over one
year |
Total | |||||||||||||||||||||||||||||||||||
Gross carrying amount | ¥ | 626,334 | ¥ | 15,341 | ¥ | 8,635 | ¥ | 5,692 | ¥ | 12,010 | ¥ | 7,893 | ¥ | 675,905 | |||||||||||||||||||||||||||
Impairment loss allowance | (748) | (316) | (168) | (198) | (438) | (3,329) | (5,197) | ||||||||||||||||||||||||||||||||||
Net carrying amount | 625,586 | 15,025 | 8,467 | 5,494 | 11,572 | 4,564 | 670,708 | ||||||||||||||||||||||||||||||||||
Weighted average loss rate (%) | 0.1 | % | 2.1 | % | 1.9 | % | 3.5 | % | 3.6 | % | 42.2 | % | 0.8 | % |
JPY (millions) except for percentage
As of March 31, 2021 |
|||||||||||||||||||||||||||||||||||||||||
Amount past due | |||||||||||||||||||||||||||||||||||||||||
Current |
Within 30
days |
Over 30 days but within 60 days | Over 60 days but within 90 days | Over 90 days but within one year |
Over one
year |
Total | |||||||||||||||||||||||||||||||||||
Gross carrying amount | ¥ | 643,819 | ¥ | 17,632 | ¥ | 12,017 | ¥ | 6,214 | ¥ | 16,762 | ¥ | 19,680 | ¥ | 716,124 | |||||||||||||||||||||||||||
Impairment loss allowance | (1,336) | (20) | (11) | (120) | (646) | (6,504) | (8,637) | ||||||||||||||||||||||||||||||||||
Net carrying amount | 642,483 | 17,612 | 12,006 | 6,094 | 16,116 | 13,176 | 707,487 | ||||||||||||||||||||||||||||||||||
Weighted average loss rate (%) | 0.2 | % | 0.1 | % | 0.1 | % | 1.9 | % | 3.9 | % | 33.0 | % | 1.2 | % |
For the Year Ended March 31 | |||||||||||||||||||||||||||||||||||
2019 | 2020 | 2021 | |||||||||||||||||||||||||||||||||
Number of options
(shares)
|
Weighted average exercise price
(JPY)
|
Number of options
(shares)
|
Weighted average exercise price
(JPY)
|
Number of options
(shares)
|
Weighted average exercise price
(JPY)
|
||||||||||||||||||||||||||||||
As of beginning of the year
|
3,403,800 | ¥ | 4,054 | 3,389,200 | ¥ | 4,055 | 3,371,200 | ¥ | 4,065 | ||||||||||||||||||||||||||
Exercised
|
(14,600) | 3,721 | (18,000) | 2,266 | (14,000) | 1 | |||||||||||||||||||||||||||||
As of end of the year
|
3,389,200 | 4,055 | 3,371,200 | 4,065 | 3,357,200 | 4,082 |
For the Year Ended March 31 | |||||||||||||||||
2019 | 2020 | 2021 | |||||||||||||||
BIP: | |||||||||||||||||
Weighted average fair value at grant date | ¥ | 4,631 | ¥ | 3,857 | ¥ | 3,765 | |||||||||||
ESOP: | |||||||||||||||||
Weighted average fair value at grant date | 4,678 | 3,857 | 3,765 | ||||||||||||||
Equity-Settled LTIP: | |||||||||||||||||
Weighted average fair value at grant date |
1,907
(US$17.64 in contractual currency)
|
For the Year Ended March 31 | |||||||||||||||||||||||||||||||||||||||||
2019 | 2020 | 2021 | |||||||||||||||||||||||||||||||||||||||
BIP | ESOP | BIP | ESOP | BIP | ESOP | Equity-Settled LTIP | |||||||||||||||||||||||||||||||||||
At beginning of the year | 433,260 | 6,891,762 | 485,232 | 7,939,675 | 819,229 | 13,398,751 | — | ||||||||||||||||||||||||||||||||||
Granted | 252,647 | 5,021,627 | 591,508 | 11,152,440 | 518,965 | 791,687 | 25,223,010 | ||||||||||||||||||||||||||||||||||
Forfeited/expired before vesting | (17,832) | (781,033) | (22,689) | (2,003,789) | — | (794,005) | (1,744,170) | ||||||||||||||||||||||||||||||||||
Settled | (182,843) | (3,192,681) | (234,822) | (3,689,575) | (302,351) | (5,644,481) | — | ||||||||||||||||||||||||||||||||||
Transfer to Cash-Settled LTIP | — | — | — | — | — | — | (65,846) | ||||||||||||||||||||||||||||||||||
At end of the year | 485,232 | 7,939,675 | 819,229 | 13,398,751 | 1,035,843 | 7,751,952 | 23,412,994 |
For the Year Ended March 31 | |||||||||||||||||||||||||||||||||||
2019 | 2020 | 2021 | |||||||||||||||||||||||||||||||||
Number of PSARs |
Weighted average exercise price
(JPY) |
Number of PSARs |
Weighted average exercise price
(JPY) |
Number of PSARs |
Weighted average exercise price
(JPY) |
||||||||||||||||||||||||||||||
As of beginning of the year | 4,584,937 | ¥ | 4,650 | 4,175,347 | ¥ | 4,849 | 2,686,749 | ¥ | 4,873 | ||||||||||||||||||||||||||
Exercised | (214,296) | 4,428 | (17,737) | 4,284 | — | — | |||||||||||||||||||||||||||||
Forfeited/expired after vesting | (195,294) | 4,940 | (1,470,861) | 4,562 | (416,310) | 4,641 | |||||||||||||||||||||||||||||
As of end of the year | 4,175,347 | 4,849 | 2,686,749 | 4,873 | 2,270,439 | 4,997 |
For the Year Ended March 31 | |||||||||||||||||
2019 | 2020 | 2021 | |||||||||||||||
As of the beginning of the year | 398,479 | 401,153 | 1,439,536 | ||||||||||||||
Granted | 279,436 | 1,403,045 | 23,541 | ||||||||||||||
Forfeited/expired before vesting | (92,829) | (188,383) | (155,551) | ||||||||||||||
Settled | (183,933) | (176,279) | (529,075) | ||||||||||||||
As of the end of the year | 401,153 | 1,439,536 | 778,451 |
For the Year Ended March 31 | |||||||||||||||||
2021 | |||||||||||||||||
As of the beginning of the year | — | ||||||||||||||||
Granted | 286,316 | ||||||||||||||||
Forfeited/expired before vesting | (29,478) | ||||||||||||||||
Settled | (59,690) | ||||||||||||||||
Transfer from Equity-Settled LTIP | 65,846 | ||||||||||||||||
As of the end of the year | 262,994 |
Company name | Country | Voting share capital Hd | ||||||||||||
Takeda Austria GmbH | Austria | 100.0% | ||||||||||||
Baxter AG | Austria | 100.0% | ||||||||||||
Baxatla Innovations GmbH | Austria | 100.0% | ||||||||||||
Takeda Distribuidora Ltda. | Brazil | 100.0% | ||||||||||||
Takeda Canada Inc. | Canada | 100.0% | ||||||||||||
Takeda (China) Holdings Co., Ltd. | China | 100.0% | ||||||||||||
Takeda Pharmaceutical (China) Company Limited | China | 100.0% | ||||||||||||
Takeda (China) International Trading | China | 100.0% | ||||||||||||
Takeda Pharma A/S | Denmark | 100.0% | ||||||||||||
Takeda France S.A.S. | France | 100.0% | ||||||||||||
Takeda GmbH | Germany | 100.0% | ||||||||||||
Takeda Ireland Limited | Ireland | 100.0% | ||||||||||||
Shire Pharmaceuticals International Unlimited Company | Ireland | 100.0% | ||||||||||||
Shire Pharmaceuticals Ireland Limited | Ireland | 100.0% | ||||||||||||
Shire Acquisitions Investments Ireland Designated Activity Company | Ireland | 100.0% | ||||||||||||
Shire Ireland Finance Trading Limited | Ireland | 100.0% | ||||||||||||
Takeda Italia S.p.A. | Italy | 100.0% | ||||||||||||
Nihon Pharmaceutical Co., Ltd. | Japan | 87.3% | ||||||||||||
Takeda Pharmaceuticals Korea Co., Ltd. | Korea | 100.0% | ||||||||||||
Takeda AS | Norway | 100.0% | ||||||||||||
Takeda Pharmaceuticals Limited Liability Company | Russia | 100.0% | ||||||||||||
Takeda Development Center Asia, Pte. Ltd. | Singapore | 100.0% | ||||||||||||
Takeda Farmaceutica Espana S.A. | Spain | 100.0% | ||||||||||||
Takeda Pharmaceuticals International AG | Switzerland | 100.0% | ||||||||||||
Baxalta GmbH | Switzerland | 100.0% | ||||||||||||
Baxalta Manufacturing, S.a.r.l. | Switzerland | 100.0% | ||||||||||||
Takeda UK Limited | United Kingdom (“U.K.”) | 100.0% | ||||||||||||
Takeda Development Centre
Europe Ltd. |
U.K. | 100.0% | ||||||||||||
Shire Pharmaceuticals Limited | U.K. | 100.0% | ||||||||||||
Takeda Pharmaceuticals U.S.A., Inc. | U.S. | 100.0% | ||||||||||||
Millennium Pharmaceuticals, Inc. | U.S. | 100.0% | ||||||||||||
ARIAD Pharmaceuticals, Inc. | U.S. | 100.0% | ||||||||||||
Takeda California, Inc. | U.S. | 100.0% | ||||||||||||
Takeda Vaccines, Inc. | U.S. | 100.0% | ||||||||||||
Takeda Development Center Americas, Inc. | U.S. | 100.0% | ||||||||||||
Baxalta Incorporated | U.S. | 100.0% | ||||||||||||
Dyax Corp. | U.S. | 100.0% | ||||||||||||
Takeda Ventures, Inc. | U.S. | 100.0% | ||||||||||||
Baxalta US Inc. | U.S. | 100.0% | ||||||||||||
200 immaterial subsidiaries
|
Company name | Country | Voting share capital Hd | ||||||||||||
Amato Pharmaceutical Products, Ltd. | Japan | 30.0% | ||||||||||||
Teva Takeda Pharma Ltd. | Japan | 49.0% | ||||||||||||
19 immaterial associates
|
JPY (millions)
As of March 31 |
|||||||||||
2020 | 2021 | ||||||||||
Trade receivables | ¥ | 1,456 | ¥ | 1,336 | |||||||
Other receivables | 2,612 | 1,841 | |||||||||
Other payables | 23,733 | 21,339 |
JPY (millions)
Amount |
|||||
Cash | ¥ | 3,029,431 | |||
Equity of the Company (770,303,013 shares)
|
3,131,282 | ||||
Cash for cash settled awards | 52,622 | ||||
Total | ¥ | 6,213,335 |
JPY (millions) | |||||
For the Year Ended March 31, 2019 | |||||
Revenue | ¥ | 3,412,468 | |||
Net profit | 53,900 |
JPY (millions)
Amount |
|||||
Cash | ¥ | 67,319 | |||
The ordinary shares of TiGenix already owned by Takeda immediately prior to the acquisition date | 2,684 | ||||
Total | ¥ | 70,003 |
JPY (millions)
Amount |
|||||
Intangible assets | ¥ | 63,421 | |||
Other assets | 5,541 | ||||
Deferred tax liabilities | (8,043) | ||||
Other liabilities | (5,678) | ||||
Basis adjustments | (3,381) | ||||
Goodwill | 18,143 | ||||
Net assets acquired | ¥ | 70,003 |
Board of Directors Charter | ||||||||
Article 1: (Purpose)
The Board of Directors of Takeda Pharmaceutical Company Limited (the “Company”) shall comply with this charter unless otherwise prescribed by the applicable laws and ordinances, or the Articles of Incorporation.
Article 2: (Meetings)
Meetings of the Board of Directors shall be convened by the Chairman of the Board of Directors.
(2) In the event the office of the Chairman of the Board of Directors is vacant or he/she cannot take an action due to some impedance, another director shall serve in an order of precedence which is determined in advance by the Board of Directors.
(3) Convocation notice of a meeting shall be dispatched to each director at least three (3) days prior to the scheduled date of the meeting. Notwithstanding, this period may be shortened in cases of emergency.
(4) Convocation procedures may be omitted in the convocation of a meeting of the Board of Directors when the unanimous consent of all directors is obtained.
(5) To request convocation of a meeting of the Board of Directors, a director shall submit to the Chairman of the Board of Directors a document in writing setting forth the matters that are the object of the meeting.
(6) Notwithstanding the provisions of Paragraph 1, 2 and 5 of this Article, the Audit and Supervisory Committee Member selected by the Audit and Supervisory Committee may convene the meetings of the Board of Directors, subject to the manner stipulated in Paragraph 3 of this Article.
Article 3: (Chair)
The Chairman of the Board of Directors shall serve as the Chair for meetings of the Board of Directors.
(2) In the event the office of the Chairman of the Board of Directors is vacant or he/she cannot take an action due to some impedance, Paragraph 2 of Article 2 shall apply mutatis mutandis.
Article 4: (Time and place of meeting)
Meetings of the Board of Directors shall be held at least once every 3 months and at least 6 times a year, and shall be held on an as-needed basis.
(2) Meetings of the Board of Directors shall in principle be held at the Global Headquarters. However, meetings may be held at any other place when necessary.
Article 5: (Meeting via video conferencing and telephone conferencing)
Meetings of the Board of Directors may be conducted by making use of video conferencing systems and/or telephone conferencing systems.
|
Article 6: (Matters to be resolved by the Board of Directors
The matters listed as “Board Resolution Matters” in the Attachment shall be resolved by the Board of Directors.
Article 7: (Resolution procedures)
Resolutions of the Board of Directors shall require a majority vote of the attending directors at a meeting under the presence of the majority of the directors.
(2)Directors with special interests in matters to be resolved as provided for in Paragraph 1 of Article 7 are prohibited from participating in resolutions. In such circumstances, the number of directors provided for in Paragraph 1 of Article 7 shall not include the number of the said interested directors.
Article 8: (Resolution in writing)
Notwithstanding the provisions of Article 7, the Board of Directors shall be deemed to have taken a resolution regarding a matter to be resolved by the Board of Directors when all directors express consent in written or electronic form.
Article 9: (Reporting on the execution of duties)
Executive Directors shall report to the Board of Directors regarding the status of the execution of their duties. The matters listed as “Board Reporting Matters” in the Attachment shall be reported to the Board of Directors.
(2)Executive Directors may cause other directors or employees to furnish reports pursuant to the preceding paragraph.
(3)Directors engaging in any of the transactions stipulated in each item of Paragraph 1, Article 356 of the Companies Act shall report material facts with respect to said transaction to the Board of Directors without delay.
Article 10: (Written reports)
Reporting to the Board of Directors shall not be required in the event that a director or accounting auditor notifies all directors in writing of matters to be reported to the Board of Directors.
(2)The provisions of Paragraph 1 of Article 10 shall not apply to reports on the status of execution of duties by directors pursuant to Paragraph 2, Article 363 of the Companies Act.
Article 11: (Attendance of employees)
The Chair may, when necessary, cause employees to attend as observers.
|
Article 12: (Minutes of the Board of Directors’ meeting)
The minutes of the Board of Directors’ meeting shall be prepared outlining the course of discussions, results and other necessary matters with respect to the agenda. The directors present shall put their seals on their typewritten name. The said minutes shall be kept at the Osaka head office for a period of 10 years.
(2) In the event that a resolution is deemed to have been taken by the Board of Directors pursuant to Article 8, and in the event that actual reporting at the Board of Directors’ meeting is not required as written report has been delivered pursuant to Article 10, minutes shall be prepared noting the nature of said matters or other necessary matters and shall be kept at the headquarters for a period of 10 years.
Article 13: (Secretariat for the Board of Directors)
Japan Legal shall serve as the Secretariat for the Board of Directors and shall arrange and coordinate agenda for the meeting and the matters to be resolved by and to be reported to the Board of Directors, dispatch the convocation notice, prepare the draft minutes of the Board Directors’ meeting and keep the minutes and provide other secretarial services.
Article 14: (Amendment)
This charter may be amended by resolution of the Board of Directors.
|
Attachment (The detail of each item is described in Takeda Group’s Management Policy (T-MAP).)
<Board Resolution Matters>
1.Important management policies and business plans
2.Basic policy for internal control systems in the Takeda Group
3.Policy for important lawsuits and disputes of the Company and subsidiaries
4.Important matters with respect to organizations, and internal regulations
5.Transfer or acceptance of transfer of businesses, and reorganization of the Company which requires the resolution of a General Meeting of Shareholders
6.Matters with material impact on the Company’s shares
7.Important matters with respect to the shareholders of the Company
8.Annual accounts and quarterly accounts for the Company
9.Matters with respect to the officers of the Company
10.Approval of transactions by a Takeda Executive Team member (or his/her relatives) with the Company or Takeda Group Companies
11.Approval of transactions with the Company or Takeda Group Companies conducted by a shareholder (or his/her close family members) holding 10% or more of the shares of the Company or a non-consolidated subsidiary at which the Company holds 10% or more of its equity interest
12.Other matters to be determined by the Board of Directors pursuant to applicable laws and ordinances or the Articles of Incorporation
13.Other especially important business execution matters in the Company or in subsidiaries
14.Other matters deemed necessary by the Board of Directors
<Board Reporting Matters>
1.Regular reporting matters (business update by President & CEO, decision status of the management committees, consolidated financial results, important personnel affairs, etc.)
2.Material matters with respect to lawsuits, disputes and external affairs
3.Other material matters equivalent to Board resolution matters
|
||||||||
Approver | Board of Directors |
Board of Directors Charter
|
|||||||||||
Enacted: 1951.11.30
|
Implemented: 1951.11.30
|
||||||||||
Amendment date | Effective date | Amendment date | Effective date | ||||||||
1969.5.11 | 1969.5.11 |
2020. 8.1
|
2020. 8.1
|
||||||||
1975.5.28 | 1975.5.28 |
2021.3.22
|
2021.4.1
|
||||||||
1977.1.27 | 1977.1.27 | ||||||||||
1982.9.29 | 1982.10.1 | ||||||||||
1986.11.1 | 1986.11.1 | ||||||||||
1995.4.1 | 1995.4.1 | ||||||||||
1996.10.1 | 1996.10.1 | ||||||||||
1997.7.1 | 1997.7.1 | ||||||||||
1998.7.1 | 1998.6.26 | ||||||||||
2001.12.26 | 2001.10.1 | ||||||||||
2002.8.27 | 2002.9.1 | ||||||||||
2004.4.1 | 2004.4.1 | ||||||||||
2005.3.30 | 2005.3.30 | ||||||||||
2005.4.27 | 2005.4.27 | ||||||||||
2007.5.18 | 2007.6.1 | ||||||||||
2009.8.1 | 2009.8.1 | ||||||||||
2009.10.30 | 2009.11.1 | ||||||||||
2015. 4. 1 | 2015. 4. 1 | ||||||||||
2016. 4. 1 | 2016. 4. 1 | ||||||||||
2016.6.29 | 2016.6.29 | ||||||||||
2017.11.1
|
2017.6.28 | ||||||||||
2019. 2. 1 | 2019. 2. 1 | ||||||||||
2019.5.14 | 2019.5.14 | ||||||||||
2020.2.18
|
2020.2.4
|
(i) | 100% of the principal amount of the Notes being redeemed; or |
(ii) | the sum of the present values of the principal and the remaining scheduled payments of interest on the Notes being redeemed (exclusive of interest accrued to the date of redemption) that would be due if such Notes were redeemed on the applicable par call date, in each case discounted to the date of redemption on an annual basis at the Comparable Government Bond Rate plus 25 basis points in the case of the 2027 notes, 25 basis points in the case of the 2029 notes, 30 basis points in the case of the 2032 notes and 35 basis points in the case of the 2040 notes; |
(i) | the holder or beneficial owner of the Notes is an individual non-resident of Japan or a non-Japanese corporation and is liable for such taxes in respect of such Notes by reason of its (A) having some present or former connection with Japan other than the mere holding of such Notes or (B) being a person having a special relationship with us (a “specially-related person of ours”) as described in Article 6, Paragraph (4) of the Act on Special Measures Concerning Taxation of Japan (Act No. 26 of 1957, as amended) (together with the cabinet order thereunder (Cabinet Order No. 43 if 1957, as amended), the “Act on Special Taxation Measures”); |
(ii) | the holder or beneficial owner of the Notes would otherwise be exempt from any such withholding or deduction but fails to comply with any applicable requirement to provide Interest Recipient Information (as defined below) or to submit a Written Application for Tax Exemption (as defined below) to the relevant paying agent to whom the relevant Notes are presented (where presentation is required), or whose Interest Recipient Information is not duly communicated through the relevant Participant (as defined below) and the relevant international clearing organization to such paying agent; |
(iii) | the holder or beneficial owner of the Notes is for Japanese tax purposes treated as an individual resident of Japan or a Japanese corporation (except for (A) a Designated Financial Institution (as defined below) that complies with the requirement to provide Interest Recipient Information or to submit a Written Application for Tax Exemption and (B) an individual resident of Japan or a Japanese corporation that duly notifies (directly, through the relevant Participant or otherwise) the relevant paying agent of its status as not being subject to taxes to be withheld or deducted by us by reason of receipt by such individual resident of Japan or Japanese corporation of interest on such Notes through a payment handling agent in Japan appointed by it); |
(iv) | the Notes is presented for payment (where presentation is required) more than 30 days after the day on which such payment on the Notes became due or after the full payment was provided for, whichever occurs later, except to the extent the holder thereof would have been entitled to additional amounts on presenting the same for payment on the last day of such period of 30 days; |
(v) | the holder is a fiduciary or partnership or is not the sole beneficial owner of the payment of the principal of, or any interest on, any Note, and Japanese law requires the payment to be included for tax purposes in the income of a beneficiary or settlor with respect to such fiduciary or a member of such partnership or a beneficial owner, in each case, who would not have been entitled to such additional amounts had it been the holder of such Note; or |
(vi) | any combination of (i) through (v) above. |
(a) | We default for more than seven days in the payment of principal when due or for more than 30 days in the payment of interest in respect of any of the Notes of such series; |
(b) | We default in the performance or observance of any covenant, condition or provision contained in the Notes of such series or in the Indenture for a period of 90 days after written notification requesting that we remedy such default shall first have been given to us (and to the trustee in the case of notice by the holders referred to below) by the trustee or holders of at least 25% in principal amount of the then outstanding Notes of such series; |
(c) | We become bound as a consequence of a default by us in our obligations in respect of any indebtedness for borrowed moneys having a total principal amount then outstanding of at least $200,000,000 (or its equivalent in any other currency or currencies) contracted or incurred by us prematurely to repay the same, or we have defaulted in the repayment of any such indebtedness contracted or incurred by us at the later of the maturity thereof or the expiration of any applicable grace period therefor, or we have failed to pay when properly called upon to do so, and after the expiration of any applicable grace period, any guarantee contracted or incurred by us of any such indebtedness in accordance with the terms of any such guarantee; provided, however, that, prior to any judgment, if we cure any such default under such indebtedness, or it is waived by the holders of such indebtedness, in each case as may be permitted under the terms of such indebtedness, then such event of default shall be deemed to have been thereupon cured or waived; |
(e) | An encumbrancer shall have taken possession, or a trustee or receiver shall have been appointed, in bankruptcy, civil rehabilitation, reorganization or insolvency of us, of all or substantially all of our assets and undertakings and such possession or appointment shall have continued undischarged and unstayed for a period of 60 days; |
(f) | We stop payment (within the meaning of the bankruptcy law of Japan) or (otherwise than for the purposes of such a consolidation, amalgamation, merger or reconstruction) cease to carry on business or are unable to pay our debts generally as and when they fall due; |
(g) | A decree or order by any court having jurisdiction shall have been issued adjudging us bankrupt or insolvent, or approving a petition seeking with respect to us reorganization or liquidation under bankruptcy, civil rehabilitation, reorganization or insolvency law of Japan, and such decree or order shall have continued undischarged and unstayed for a period of 60 days; |
(h) | We initiate or consent to proceedings relating to us under bankruptcy, civil rehabilitation, reorganization or insolvency law of Japan or shall make a conveyance or assignment for the benefit of, or shall enter into any composition with, our creditors generally; or |
(i) | Any other event of default provided for in a supplemental Indenture to the Indenture or in the applicable Notes, as may be specified in the applicable prospectus supplement or free writing prospectus. |
(i) | change the maturity date of the principal or payment date of any interest or change any obligation of ours to pay any additional amounts; | |||||||
(ii) | reduce the principal amount of, or rate of interest on, any Notes; | |||||||
(iii) | change the redemption date or price at which Notes are redeemed; | |||||||
(iv) | affect the rights of holders of less than all the outstanding Notes; | |||||||
(v) | change the place of payment where, or the coin or currency in which, any note or interest thereon is payable; or | |||||||
(vi) | impair the right of a holder to institute suit for the enforcement of any payment on or with respect to any Notes on or after the date when due; |
(i) | to evidence the succession of another corporation, entity or person to us and the assumption by any such successor of our covenants in the Indenture and the Notes; | |||||||
(ii) | to add to our covenants or to surrender any right or power in the Indenture conferred upon us for the benefit of the holders of the Notes; | |||||||
(iii) | to evidence and provide for the acceptance of appointment under the Indenture by a successor trustee; | |||||||
(iv) | to cure any ambiguity, to correct or supplement any provision in the Indenture which may be defective or inconsistent with any other provision in the Indenture, or to make any other provisions with respect to matters or questions arising under the Indenture, provided that such action shall not adversely affect the interests of the holders of the Notes in any material respect; | |||||||
(vi) | to comply with requirements of the SEC in order to effect or maintain the qualification hereof under the Trust Indenture Act. |
Milestone Event
|
Milestone Payment
|
||||
Receipt of notice of acceptance of submission of first MAA with EME
|
$5 million
|
||||
Approval for marketing in the third (3rd) Key Country in the Licensed Territo
|
[ *** ]
|
||||
Approval of MAA by EMEA
|
[ *** ]
|
||||
Approval of MAA by and receipt of Pricing Approval from MH
|
[ *** ]
|
Milestone Event
|
Milestone Payment
|
||||
Approval for marketing in the third (3rd) Key Country in the Licensed Territo
|
$1 million
|
||||
Approval of MAA by EMEA
|
[ *** ]
|
||||
Approval of MAA by and receipt of Pricing Approval from MH
|
[ *** ]
|
Milestone Event
|
Milestone Payment
|
||||
[***]
|
[***]
|
||||
Approval of MAA by EMEA
|
$30 million
|
||||
Approval of MAA by and receipt of Pricing Approval from MH
|
$10 million
|
Milestone Event
|
Milestone Payment
|
||||
[***]
|
[***]
|
||||
[***]
|
[***]
|
||||
[***]
|
[***]
|
||||
[***]
|
[***]
|
Milestone Event
|
Milestone Payment
|
||||
[***]
|
[***]
|
||||
[***]
|
[***]
|
||||
[***]
|
[***]
|
||||
[***]
|
[***]
|
||||
[***]
|
[***]
|
Annual Net Sales Threshold
|
Sales Milestone Payment
|
||||
$100 million
|
$5 million
|
||||
$200 million
|
$20 million
|
||||
[***]
|
[***]
|
Calendar Year Net Sales of Licensed Product in the Licensed Territory
|
Royalty Rate for Net Sale
|
||||
[***]
|
[***]
|
||||
[***]
|
[***]
|
||||
[***]
|
[***]
|
||||
[***]
|
[***]
|
MILLENNIUM PHARMACEUTICALS, INC. | SEATTLE GENETICS, INC. | ||||
By: /s/ Deborah Dunsire | By: /s/ Clay B. Siegall | ||||
Name: Deborah Dunsire | Name: Clay B. Siegall | ||||
Title: President and CEO | Title: President and CEO |
/s/ Christophe Weber | ||
Christophe Weber | ||
Representative Director, President and Chief Executive Officer |
/s/ Costa Saroukos | ||
Costa Saroukos | ||
Director and Chief Financial Officer |
/s/ Christophe Weber | ||
Christophe Weber | ||
Representative Director, President and Chief Executive Officer |
/s/ Costa Saroukos | ||
Costa Saroukos | ||
Director and Chief Financial Officer |